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Abstract 
Although cancer survival rates have significantly improved over the past few 
decades, the improvements are primarily due to early diagnosis and inhibiting cancer 
growth. Limited progress has been made in the treatment of cancer metastasis, which 
contributes to 90% of cancer related deaths, and therapeutic agents targeting the various 
aspects of metastasis are lacking. One potential approach is to utilize small 
pharmacological compounds to inhibit tumour cell motility, as a strategy against tumour 
cell migration, invasion, and metastasis. The acetylenic tricyclic bis-(cyano enone), TBE-
31, has been shown to be a promising chemopreventative compound. However, its effects 
on cell migration are unknown. This thesis focuses on deciphering the molecular 
mechanisms TBE-31 utilizes to inhibit cell migration. I demonstrated that TBE-31 binds 
with cysteine 374 of actin, inhibits actin polymerization and stress fiber formation. These 
findings were applied to a model of epithelial-to-mesenchymal transition, a precursor 
event to metastasis, where I determined TBE-31 was able to inhibit the crucial 
rearrangement of cortical actin to form actin stress fibers, which prime tumour cells for 
migration. In addition to the actin cytoskeleton, I demonstrated that TBE-31 alters 
microtubule dynamics and organization. Microtubule-dependent trafficking was also 
shown to be disrupted by TBE-31, and the localization of the polarity proteins Rac1, 
IQGAP and Tiam1 were altered from the leading edge of migrating cells. Lastly, TBE-31 
was shown to inhibit Rat2 and NIH3T3 fibroblast as well as H1299 non-small cell lung 
cancer tumour cell migration. Taken together, my work provides novel insights on the 
underlying mechanisms by which TBE-31 utilizes to inhibit cell migration and provide 
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important knowledge for developing therapeutic compounds that target tumour cell 
motility in metastasis.  
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Chapter 1  
 
 
Introduction 
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1 Introduction 
1.1 Cancer Metastasis 
Cancer arises from cells that have undergone multiple genetic mutations that lead 
to the loss of normal cell behaviour 1,2. These mutations initially result in uncontrolled 
growth and proliferation. As the malignant cells continue to gain genetic mutations, a 
portion of these cells will gain the ability to migrate and invade adjacent tissue, and 
eventually disseminate to distant organs where they may establish new tumour colonies. 
These colonies are known as metastases, and are responsible for over 90% of human 
cancer related deaths 3-6. Cell migration is a key process in regulating metastasis, and to 
date effective drugs targeting metastasis are lacking 7-9.  
 
1.2 Cell Migration: an Overview 
Cell migration is a broad term used to describe the process that involves the 
translocation of cells from one location to another. This may occur in inert environments 
such as in soil, or on glass or plastic as is commonly seen in in vitro experiments, or 
within complex multicellular organisms 10-12. Cells migrate in response to stimuli from 
their environment and this plays an essential role in many major physiological processes 
such as embryogenesis, growth, development, immune response and wound healing 10-12. 
However, abnormal cell migration can contribute to pathological conditions, such as 
autoimmune diseases, chronic inflammation and cancer 10-16. 
Cell migration can be broken down into a set of component processes, which 
include front/rear polarization, protrusion, adhesion, translocation of the cell body, and 
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retraction of the rear (Figure 1.1). These processes are orchestrated by a network of both 
intracellular and extracellular signaling molecules and the cytoskeleton 10-12. Although it 
is helpful to think of these as separate, individual processes, in actual fact they flow 
seamlessly from one another or overlap each other. We begin with a cursory overview of 
the entire process before examining the major cellular components in more detail. 
 
1.2.1 Polarization 
Cell polarization is often thought of as the initial step in cell migration. 
Polarization in cell migration refers to the tendency of a migrating cell to have a distinct 
front or leading edge, and a rear or lagging end. This is often stimulated and reinforced 
by environmental cues. These cues can be chemotactic (induced by chemoattractants or 
morphogens), haptotactic (from varying concentrations of substrate), mechanotactic 
(breakdown of cell-cell contacts), electrotactic (induced by electric fields), durotactic 
(due to differences in pliability), or a combination of these. The microtubule network 
rearranges, polarity proteins are delivered to the leading edge, and actin polymerization 
begins 10-12,17,18. 
 
1.2.2 Protrusion 
Protrusions are the de novo formation of extensions in the plasma membrane in 
the direction of migration. The protrusion is primarily driven by the local polymerization 
of actin. Large broad, fan-like protrusions are formed by branched actin polymerization 
called lamellipodia or alternatively thin spike-like protrusions can be generated by  
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Figure 1.1 An overview of cell migration 
Cell migration begins with i) polarization of the cytoskeleton towards the direction of 
migration. The polarity proteins initiate actin polymerization to generate ii) protrusions 
in the plasma membrane known as lamellipodia. New focal iii) adhesions underneath the 
lamellipodia adhere the membrane to the substratum. Meanwhile the focal adhesions at 
the rear disassemble and the iv) cell body translocates and the rear retracts. 
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parallel bundles of actin called filopodia. These two forms of protrusions are thought to 
have different roles, with the former contributing primarily to forward movement and 
traction, and the latter providing mechanosensory and exploratory functions 10-12,19. 
 
1.2.3 Adhesion 
Focal adhesions are mainly composed of integrin receptors, a large superfamily of 
heterodimeric receptors, which form specialized attachments sites wherein cells make 
contacts with the extracellular matrix (ECM) 20. They are dynamic structures that form 
underneath the cell protrusions to provide traction to the substratum. They grow and 
shrink in size due to the recruitment and disassembly of proteins in response to 
mechanical forces. Focal adhesions are able to link the cytoskeletal network to the ECM, 
allowing cells to respond to the external environment through a feedback loop of, “inside-
outside-inside,” signaling. Cellular contractility generated by the actomyosin 
cytoskeleton is transmitted to the ECM as traction forces by focal adhesions, and cells are 
also able to sense the local extracellular environment via focal adhesions 10-12,20,21.  
 
1.2.4 Cell body translocation and retraction of the rear 
Cell body translocation and retraction of the rear are the least well-understood 
processes in cell migration. Cell body translocation involves the coordinated contraction 
of the actomyosin cytoskeleton, and the microtubule network and motor proteins such as 
dynein help translocate the nucleus and other organelles. Meanwhile at the rear, mature 
focal adhesions are disassembled and contraction of the actomyosin cytoskeleton leads to 
retraction 10-12,22. 
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As the above steps—polarization, protrusion, adhesion, cell body translocation, 
and retraction of the rear—continue to occur in a cyclical fashion, the cell will translocate 
forwards. 
 
1.3 Cell Migration: the role of Rho GTPases, actin and 
microtubules 
Cell migration is a complex, multi-step process, involving careful orchestration 
and coordination between signaling molecules and the cytoskeleton. Polarity proteins 
establish and maintain a leading edge for proper directional movement, and help regulate 
the cytoskeleton. The actin cytoskeleton provides force for protrusion, and tension for 
retraction. While the microtubules establish a network for organelle translocation and 
protein delivery 10-12. These three components, their regulation, and their contributions to 
cell migration will be covered in greater detail below. 
 
1.3.1 Polarization and the Rho GTPases 
Rho GTPases belong to the Ras superfamily of small GTPases and are highly 
conserved throughout eukaryotes. To date, over 20 Rho GTPases have been identified, 
and it is thought that each one acts as a molecular switch to control distinct biochemical 
pathways 23-25. However only Rho (three isoforms, RhoA, RhoB, and RhoC), Rac (three 
isoforms, Rac1, Rac2, and Rac3) and Cdc42 have been studied extensively. Like all 
regulatory GTPases, these proteins are found in an inactive GDP-bound conformation, 
and in an active GTP-bound conformation. The interconversion between the two is 
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regulated by three types of regulatory proteins. Guanine nucleotide exchange factors 
(GEFs) activate GTPases by catalyzing the exchange of GDP for GTP, whereas GTPase-
activating proteins (GAPs) increase the intrinsic GTP hydrolysis rate, thereby 
inactivating it (Figure 1.2A) 23-25. Guanine nucleotide dissociation inhibitors (GDIs) 
sequester the GDP-bound form of some GTPases in the cytosol, and prevent them from 
localizing to the membrane or being activated by GEFs 23-25. Rho GTPases can be 
activated directly or indirectly by various cell-surface receptors, including integrins, 
cadherins, cytokine receptors, receptor tyrosine kinases and G protein-coupled receptors 
26. In the active GTP-bound conformation, Rho GTPases can interact with a range of 
effector proteins including kinases, actin regulators and adaptor proteins, leading to 
changes in cell behaviour. The spatiotemporal regulation of each Rho GTPase is 
therefore important to determine the outcome of its activity 23-25. 
Cell migration is an inherently polarized process, with the molecular processes at 
the front different from those at the rear. Whether cell polarization is induced by a 
chemical gradient of soluble or membrane-bound chemoattractants, or by the localized 
activation of integrins, the recruitment and activation of the Rho GTPases, Cdc42 and 
Rac, at the leading edge are major events necessary for triggering cell polarity (Figure 
1.2B) 10-12,23-25,27. The major targets for Rac and Cdc42 that mediate actin polymerization 
in protrusions are the Wiskott–Aldrich syndrome protein (WASP)/WASP-family 
verprolin-homologous protein (WAVE) family of actin related proteins 2 and 3 (Arp2/3) 
complex activators. Rac1 stimulates lamellipodial extensions by activating WAVE 
proteins, while Cdc42 binds to WASP proteins to stimulate Arp2/3. Cdc42 also affects  
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Figure 1.2 Rho GTPases and cell migration 
A) Rho GTPases can exist in an active (GTP-bound) or an inactive (GDP-bound) 
confirmation. In the active state, they interact with target (effector) proteins to induce a 
cellular response. Most Rho GTPases have an intrinsic ability to hydrolyze the GTP to 
GDP and inorganic phosphate (Pi), but it is also promoted by Rho GTPase-activating 
proteins (GAPs). The exchange of GDP for GTP is promoted by Rho guanine nucleotide 
exchange factors (GEFs). In addition, when in the GDP-bound state, the Rho GTPases 
can interact with Rho GDP dissociation inhibitor (GDI), which sequester the complex 
and prevent reactivation. 
B) During cell migration, external signals from the environment (for e.g. interaction with 
the ECM, or soluble signals) activate Cdc42, Rac1 and RhoA to establish front-rear 
polarity. Cdc42 binds to Par6, which activates aPKC. This promotes the local 
phosphorylation and inhibition of GSK3, leading to rearrangements of the microtubule 
network through microtubule-associated proteins (MAPs). Cdc42 and Rac1 activate 
WASP and WAVE respectively, which in turn promotes branched actin polymerization 
through Arp2/3 and promote lamellipodia formation. Cdc42 also acts on formin to 
promote stress fiber formation and filopodia at the leading edge. Similarly, RhoA 
activated formin, myosin II and ROCK to promote stress fiber formation and retraction at 
the rear.  
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polarity by localizing the microtubule-organizing center (MTOC) and Golgi apparatus in 
front of the nucleus, to orient the two towards the leading edge. This aids in the 
microtubule-mediated delivery of Golgi-derived vesicles to the leading edge, providing 
membrane and associated proteins for protrusion 1-3,9-11,13.These processes will be 
covered in greater detail in the following actin and microtubule descriptions. 
 
1.3.2 The Actin Cytoskeleton 
1.3.2.1 Structure  
Actin is the most abundant protein in most eukaryotic cells 28, and is expressed in 
three main isoforms, α, β, and γ. There are three α-isoforms found in skeletal, cardiac and 
smooth muscles, while β- and γ- isoforms are expressed in non-muscle and muscle cells. 
The actin structure is highly conserved and the isoforms only differ by a few amino acids 
28,29. Actin is found both in globular monomeric (G-actin) or polymeric filamentous (F-
actin) forms. The 375 amino acid, 42 kDa protein, folds into two major α/β domains, also 
often respectively referred to as the outer and inner domains due to their locations in 
filamentous actin, or the small and large domains due to their apparent size difference 
observed by electron microscopy. Each domain can be further divided into two 
subdomains for a total of four domains 28,30. The polypeptide chain passes twice through 
the two major domains at residue Lys336 and at linker helix Gln137-Ser145, which 
functions as a hinge between these two domains. As a result, two clefts between the 
domains are formed. The upper cleft binds nucleotides and associated divalent cations 
(i.e. Mg2+), which form another important linkage between the two major domains. The 
lower cleft contains primarily hydrophobic residues and is important in mediating 
12 
 
longitudinal contacts between actin subunits in the filament. In addition, this hydrophobic 
cleft is the major binding site for most actin-binding proteins, and small molecules, and is 
thus often called the target binding cleft 28,31. The actin monomers polymerize to form the 
actin filaments, which are constructed with two chains of actin that turn gradually around 
each other to form a two-chained long helix 28. 
 
1.3.2.2 Actin Polymerization 
The first step in actin polymerization is nucleation, which is defined as the 
formation of a stable multimer of actin monomers. This occurs slowly, and is the rate-
limitimg step in polymerization due to the relative instability of actin dimer intermediates 
and the activity of actin monomer sequestering proteins that suppress spontaneous 
nucleation in cells 32. However, once a nucleus is formed, actin polymerization proceeds 
quickly at the barbed fast growing plus end, and more slowly at the pointed minus end. 
The ATPase activity of actin increases upon incorporation into the filament, and causes 
the spontaneous hydrolysis of the bound ATP to ADP. This destabilizes the filament and 
the ADP-actin dissociates and undergoes nucleotide exchange to revert back to ATP-
actin. This in turn provides more actin monomers for polymerization at the positive end. 
The constant recycling of actin results in actin treadmilling (Figure 1.3A) 32-34.  
The rates of nucleation and treadmilling of pure actin are far too slow to account 
for the rates of cell migration, and a number of actin binding proteins are responsible for 
facilitating nucleation and promote elongation 34. Filament nucleators bear little overall  
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Figure 1.3 The actin cytoskeleton and cell migration 
A) Actin treadmilling. i) Formation of actin oligomers are unfavourable. ii) Once an actin 
nucleus is formed, the association of monomers proceeds quickly. The plus (+) end grows 
much faster than the minus (-) end. iii) Hydrolysis of ATP and the dissociation of 
phosphate destabilizes the actin and causes depolymerization. Dissociated ADP-actin 
undergoes nucleotide exchange, and the resulting ATP-actin recycles back to the plus 
end. iv) Rates of treadmilling are greatly increased by the actin depolymerizing factor 
(ADF)/Cofilin family and Profilin. ADF/Cofilin facilitate the depolymerization of ADP-
actin, and Profilin facilitates nucleotide exchange of ADP-actin to ATP-actin. 
B) Fascin bundles actin filaments to produce actin stress fibers. 
C) When active, the actin-related protein 2/3 (Arp2/3) complex binds to the side of pre-
existing actin filaments to provide nucleation sites for actin, which results in a branched 
array of actin filaments. 
D) At the leading edge, stress fibers form spike-like protrusions in the plasma membrane 
known as filopodia, and the branched actin forms a broad fan-like protrusion of plasma 
membrane called the lamellipodia. Stress fibers are also present in the cell body and aid 
in retraction of the rear. 
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resemblance to one another, but all include the WASP-homology 2 (WH2) domain for 
interacting with actin. Known nucleators include Arp2/3 complex and its large family of 
nucleation promoting factors, Spire, CObl, VopL/VOpF, TARP and Lmod 28,34. 
Elongation factors also include a wide variety of formins—which are modular proteins 
characterized by the presence of two conserved domains, formin homology 1 and 2 (FH1 
ad FH2), as well as Ena/VASP 28,34. Actin depolymerizing factor (ADF) also known as 
cofilin, can induce ADP-actin depolymerization at the minus end 35,36, while profilin 
facilitates the nucleotide exchange of ADP-actin to ATP 37. The combined effect of ADF 
and profilin enhances the rate of actin treadmilling by 125-fold alone 34,38. A number of 
other actin binding proteins also help regulate the temporal and spatial organization of the 
overall actin cytoskeleton. There are three main types of actin-based structures found 
within the cell: filopodia, lamellipodia, and stress fibers (Figure 1.3D)39. 
 
1.3.2.3 Branched Actin and the Lamellipodia 
During cell migration, the localization of Rac1 and Cdc42 activate the family of 
WASP proteins, which includes the ubiquitous neural-Wasp (N-WASP), and suppressor 
of cAMP receptor (SCAR)/WAVE isoforms 1, 2 and 3. These proteins in turn activate 
Arp2/3. Arp2/3 is a complex of seven conserved subunits including the two actin related 
proteins Arp2 and Arp3, and ARPC1, ARPC2, ARPC3, ARPC4 and ARPC5 34,40. The 
Arp2/3 activators help bring actin monomers close in proximity to the Arp2/3 complex, 
once incorporated into an actin filament the complex provides a new nucleation point for 
a daughter filament, which elongates at 70 degrees from the mother filament, thus 
forming a branched array of actin filaments (Figure 1.3C) 40,41. During cell migration, this 
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branched actin network forms the basis of the lamellipodia, the broad fan-like plasma 
membrane projection that provides the primary form of forward locomotion 42. 
 
1.3.2.4 Unbranched Actin; Filopodia and Stress Fibers  
In contrast to branched actin, unbranched actin (also known as linear, or 
processive actin) assembly contribute to creating actin structures such as filopodia, stress 
fibers and actin arcs 39. Cofilin can sever existing actin filaments to provide more barbed 
ends to provide sites for actin polymerization and Fascin can bundle actin filaments to 
promote the formation of filopodia—the spike-like projections that function as 
mechanosensory, and exploratory devices 35,36,43. RhoA directly promotes stress fiber 
assembly through its effectors, RhoA-associated protein kinase (ROCK) and the formin 
mDia1 (mammalian Dia1; also known as DIAPH1 and DRF1). mDia1 promotes the 
polymerization of long parallel actin filaments, whereas ROCK inhibits cofilin through 
activation of LIM domain kinase 1 (LIMK1), ensuring that the forming actin filaments do 
not get severed 39. Stress fibers provide structure, and during cell migration, these actin 
stress fibres are found to associate with focal adhesions, and help provide a contractile 
force to retract the lagging end of the cell (Figure 1.3D) 22,39,44,45. Actin arcs are similar to 
actin stress fibers in that they also provide structure, but do not directly attach to focal 
adhesions, and display a periodic α-actinin-myosin pattern which contribute to their arc 
structure and give them the ability to contract 39,46. 
1.3.3 The Microtubule Network 
Microtubules (MTs) are noncovalent polymers of the protein tubulin found in all 
dividing eukaryotic cells and in nearly all differentiated cell types. During cell division, a 
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large dynamic array of MTs called the mitotic spindle facilitates the physical separation 
of chromosomes and serves to orient the plane of cleavage. In non-dividing cells, MTs 
organize the cytoplasm, position the nucleus and organelles, and serve as the primary 
structural components of the flagella and cilia 47,48. During cell migration MTs help 
establish and maintain the spatial and temporal coordination of migratory signals and 
events 27,47,49. 
 
1.3.3.1 Microtubule structure and dynamics 
Microtubules are composed of heterodimers made up of α and β-tubulin 
monomers, which are approximately 50% identical to each other at the amino acid level 
and have a molecular mass of approximately 50 kDa 47. These heterodimers are aligned 
in a polar head-to-tail fashion to form protofilaments and they associate laterally to form 
a 25 nm wide hollow cylindrical microtubule (Figure 1.4A, B and C). The heterodimers 
associate in the same direction and generate a polarized filament with a distinctive minus 
and plus end. In a cell, the minus end is anchored to the microtubule organizing center 
(MTOC), while the plus end is free to associate with heterodimers to further elongate 
47,50. This polymerization is regulated by the hydrolysis of β-tubulin bound GTP (GTP 
bound to α-tubulin is non-exchangeable and is never hydrolyzed), which occurs with a 
delay after the tubulin heterodimer has been incorporated into the microtubule end. As a 
result the newly formed microtubule tip contains a cap of GTP-tubulin, which helps 
stabilize the structure, whereas the shaft of the microtubule is composed of GDP-tubulin 
and is intrinsically less stable. In the presence of the cap a microtubule continues to grow, 
and a loss of the cap leads to rapid microtubule shrinkage, termed catastrophe. For this
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Figure 1.4 The microtubule network and cell migration 
A) Microtubules are composed of subunits of tubulin heterodimers formed from tightly 
linked α- and β- tubulin monomers. The GTP molecule in the α-tubulin does not 
hydrolyze to GDP, however the GTP molecule in β-tubulin does, which plays an 
important role in filament dynamics. 
B) The tubulin heterodimers align in a head-to-tail fashion to generate a polarized 
protofilament. 
C) The protofilaments associate laterally to form a 25 nm wide hollow cylindrical tube 
known as a microtubule. 
D) Microtubules are under a state of dynamic instability, characterized by polymerizing 
(left) and depolymerizing microtubules (right). GTP-tubulin is incorporated at 
polymerizing microtubule ends. The GTP is quickly hydrolyzed soon after 
polymerization and phosphate is released, resulting in a GDP-tubulins shaft which is 
intrinsically less stable than the GTP-tubulin cap. If a GTP-tubulin cap is not maintained 
by incoming GTP-tubulin, the GDP-tubulin shaft depolymerizes (termed catastrophe). As 
GTP-tubulin is replenished, the microtubule can transit back to polymerization (rescue). 
The microtubules infrequently pause in a state, neither gaining nor losing tubulin subunits 
and these tubulin heterodimers lie within a fully formed cylinder (bottom). 
E) During cell migration, microtubules polarize, and maintain front-rear polarity by 
coordinating specific cellular activities, including the transport of membrane vesicles to 
the leading edge.  
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reason, the microtubules are under a constant state of ebb and flow termed dynamic 
instability, which is dependent on capping proteins and monomer concentration (Figure 
1.4D). The nature of this instability helps the microtubule distribute in the cell during 
cytoskeletal reorganization and undergo a, “search and capture,” process where the tip of 
the microtubule shrinks and grows to explore the extracellular space until capturing an 
organelle or microtubule associate protein 47,50. 
 
1.3.3.2 Regulation and function in cell migration 
Microtubules have long been implicated in cell migration, however the 
mechanism of their involvement has remained unclear, and has even been considered 
controversial at times. Most studies have concluded that microtubules play a positive role 
in cell migration by regulating actin polymerization, transporting membrane vesicles to 
the leading edge and/or facilitating the turnover of focal adhesions 49,51-53. In general, 
their greatest contribution is to maintain a polarized intracellular organizations and 
correctly coordinate the position of specific cellular activities (Figure 1.4E) 27,49,54.  
The local activation of Cdc42 is a crucial early event in cell migration leading to the 
polarization of the microtubule network. Cdc42 can be activated by a wide variety of 
polarity cues 55. In a scratch-induced migration assay, integrin engagement leads Src- and 
Scrb-dependent activation of the protein βPIX, which in turn acts as Cdc42 specific GEF. 
βPIX also contributes to the recruitment of Rac1, but is activated independently 55-57. 
Cellular redistribution of Cdc42 can also be initiated by soluble ligands acting as 
membrane bound or membrane permeable chemoattractants. This mirrors the 
establishment of an intracellular phosphoinositide gradient established by the activation 
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of PI3K at the front and PTEN at the back 55,58,59. Once activated, Cdc42 binds and 
recruits Par6, and activates atypical protein kinase C (aPKC), which in turn promotes the 
local phosphorylation and inactivation of GSK3 kinases. GSK3 is a constitutively active 
serine/threonine kinase that regulates several +TIPs (microtubule plus-end tracking 
proteins, a subclass of microtubule-associated proteins (MAPs)) and stabilizes a number 
of MAPs. GSK3β can phosphorylate stathmin and help establish a gradient of stathmin 
activity, which promotes microtubule growth at the leading edge and depolymerization at 
the rear 55,60,61. The inhibition of GSK3β at the leading edge also promotes the 
recruitment of APC 55. APC functions to help promote microtubule growth, but also 
microtubule capture to the leading edge via the enhanced binding of IQGAP1 to Clip-170 
12,55,62. 
 
1.4 Metastasis Cascade  
Cell migration requires a complex orchestration of numerous proteins, and not 
surprisingly, the dysregulation of any of these can lead to pathological diseases. In the 
later stages of cancer, cell migration is exploited to allow tumour cells to spread to new 
areas of the body in a process called metastasis. Metastasis is responsible for 90% of all 
cancer related deaths, yet it remains the most poorly understood component of cancer 
pathogenesis 3-6. The basic steps of metastasis include the invasion of tumour cells into 
the local tissue, intravasation into the lymph or blood system, dissemination, 
extravasation, and colonization at distant organs (Figure 1.5) 6,63. These steps will be 
covered in greater detail below. 
  
24 
 
Figure 1.5 The metastasis cascade 
During metastasis progression, tumour cells acquire a more invasive phenotype through a 
process termed epithelial-to-mesenchymal transition and exit their primary site of growth 
and invade into the surrounding extracellular matrix (local invasion). When the cancer 
cells reach the blood vessels, they can enter into the circulatory system (intravasation) 
and distribute throughout the body (dissemination). Eventually the tumour cells will 
arrest at a distant site, exit the circulation and invade the microenvironment of a foreign 
tissue (extravasation). At the foreign site, the cancer cells must adapt to survive and 
thrive (micrometastasis) before developing into full colonies (macrometastasis). 
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1.4.1 Local Invasion and Epithelial-to-Mesenchymal Transition 
Local invasion involves the entry of cancer cells that have resided within a well-
confined primary tumour into the surrounding tumour-associated stroma, and then into 
the adjacent tissue parenchyma. The first barrier to invasion is the basement membrane, a 
specialized extracellular matrix component that plays a vital role in organizing the 
epithelial tissue by separating the epithelium from the stroma. Epithelial cells are highly 
organized and form sheet-like layers that are held together by complexes such as tight 
junctions, adherens junctions and desmosomes. In addition, they display apical-basal 
polarity and are attached to the basement membrane. The precisely controlled tissue 
architecture of normal epithelium keep the epithelial cells relatively immobile and serve 
as an intrinsic barrier for tumour cell migration and invasion 14-16,63,64. 
In order to overcome this and other obstacles for invasion, carcinoma cells may 
co-opt a cell-biological program known as epithelial-to-mesenchymal transition (EMT) 
(Figure 1.6) EMT is normally a critical process for healthy embryonic morphogenesis 
where cells transition between epithelial and mesenchymal states in a highly plastic and 
dynamic manner 65. EMT programs are orchestrated by a set of pleiotropically acting 
transcription factors (TFs)—including Slug, Snail, Twist, ZEB1, and ZEB2—which 
trigger the entrance into a mesenchymal state by suppressing expression of epithelial 
markers and inducing the expression of other markers associated with mesenchymal cells 
14,63,65. Cell-cell junctional proteins, like E-cadherin, which normally tethers epithelial 
cells into sheets, are repressed, and N-cadherin, which is associated with mesenchymal 
and migratory cells, are up-regulated 66. The actin cytoskeleton rearranges from the cell 
cortex to form actin stress fibers, and the overall apical-basal polarity is lost. 
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Figure 1.6 Epithelial-to-mesenchymal transition 
Epithelial-to-mesenchymal transition (EMT) is an important process during development, 
but also marks an important event during tumour progression where cells become more 
invasive and metastatic. Key events include the disruption of cell-cell junctional 
complexes—such as tight junctions, adherens junctions and desmosomes—the loss of 
apical-basal polarity and a restructuring of the actin cytoskeleton from cortical actin to 
actin stress fibers. EMT also involves a shift in expression of epithelial markers (for e.g., 
E-cadherin and ZO-1) to cells that express mesenchymal markers such as N-cadherin and 
vimentin. Cells that have undergone EMT display an enhanced migratory capacity and 
increased invasive potential. The reverse process, mesenchymal-to-epithelial transition 
(MET), may also occur. 
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Consequently the precise architecture of normal epithelium is lost, and the cells begin to 
exhibit multiple mesenchymal attributes, including heightened migratory and invasive 
potential 14,63,65. In addition, the Snail and ZEB factors induce the transcription of 
metalloproteases that then degrade the basement membrane, enabling local cell invasion 
14,65. 
After undergoing EMT and dissolving the basement membrane, carcinoma cells 
migrate and invade into the stroma. Here the carcinoma cells encounter a variety of 
tumour-associated stromal cells. The resultant composition of these associated stromal 
cells is governed largely by the state of tumour progression. As the primary tumour 
progression proceeds, the stroma becomes increasingly “reactive” which is to mean that it 
acquires many of the characteristics associated with wound healing or chronic 
inflammation 63,67. Components of the tumour associated stroma can include fibroblasts, 
myofibroblasts, endothelial cells, adipocytes, and various bone marrow-derived cells—
including mesenchymal stem cells, macrophages and other immune cells 63,68. Crosstalk 
between the tumour cells and the stroma enhance the aggressive behaviours of carcinoma 
cells through various types of signaling. Therefore, there is a bi-directional interaction 
that occurs between the tumour cells and the nearby stroma, the carcinoma stimulates the 
formation of an inflamed stroma, and the stroma reciprocates enhancing the malignant 
traits of the carcinoma, establishing a self-amplifying positive feedback loop 63,68,69.  
1.4.2 Intravasation 
Entry into the stroma provides opportunities for the tumour cells to access the 
systemic circulation and disseminate to distant sites. Intravasation involves locally 
migratory and invasive carcinoma cells entering the lumen of either the lymphatic or 
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blood vessels 70. Although intravasation into the lymphatic vessels occurs and is 
important as a prognostic marker for cancer progression, intravasation into the 
hematogenous circulation appears to represent the major mechanism by which metastatic 
carcinoma cells disseminate, and this will be the primary focus in the following section 
63,70.  
Intravasation requires cancer cells to cross the endothelium, a process that is 
known as transendothelial migration (TEM). This can occur through paracellular TEM, 
which involves the disruption of junctions between adjacent endothelial cells, which 
allows the tumour cells to squeeze between them or transcellular TEM, which involves 
the migration of cancer cells directly through the endothelial cell body 71-73. Although 
most studies have shown paracellular TEM in vitro, there is evidence suggesting they can 
also use a transcellular route. Thus far, it is not clear which route is used by cancer in 
vivo, or if the route is dependent on the vasculature or cancer type 73.  
The major barrier for paracellular TEM is the presence of endothelial cell 
junctions. In vitro it has been shown that cancer cells induce endothelial cell junction 
opening by secreting various factors that activate signaling pathways in endothelial cells. 
For example, the carcinoma cells or the tumour associated stroma, such as macrophages, 
produce VEGF or TGFβ1, which can disrupt cell junctions based on VE-cadherin-β-
catenin complexes and induce endothelial cell junction opening, thus facilitating cancer 
cell TEM 73-75. Other cancers may influence endothelial cell signaling by stimulating the 
Rho GTPases to facilitate TEM by causing an increase in actomyosin contractility, and 
stress fiber-mediated tension on adherens junctions, causing an opening 73,76. Similarly, 
endothelial RhoA is activated by lung cancer attachment to endothelial cells, which 
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activate ROCKs, leading to increased stress fiber assembly, and tight-junction disruption, 
to again facilitate cancer cell TEM 73,77.  
Recent studies have provided some evidence to show that tumour cells may 
migrate through the endothelial cell body instead of only through paracellular route. 
During transcellular intravasation, the Ca2+-calmodulin complex in an endothelial cell 
activates myosin light chain (MLC) kinase (MLCK) at the site of cancer cell attachment. 
This induces a local phosphorylation of MLC and to actomyosin contraction, which leads 
to rapid actin cytoskeletal and membrane remodelling which creates a transient pore-like 
structure for the cancer cell to cross through the endothelial cell 73,76,77. 
Intravasation can occur in blood vessels normally present near the primary 
tumour, or through new blood vessels formed within the local microenvironment of the 
tumour via the process of neoangiogenesis, which can be initiated by VEGF from the 
carcinoma cells or tumour associated stroma. In contrast to the normal blood vessels, this 
neovasculature generated in response to carcinoma cells is often described as tortuous, 
prone to leakiness and in a state of continuous reconfiguration 63,78. This weakened 
vasculature is thought to facilitate tumour cell intravasation more easily. 
 
1.4.3 Survival and dissemination through the circulation 
Once the carcinoma cells have successfully intravasated into the lumen of blood 
vessels, they can disseminate widely through the venous and arterial circulation. 
However they must survive a variety of stresses in order to reach distant organs 63. For 
example, in the absence of integrin-dependent adhesion to the extracellular matrix, 
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epithelial cells would normally undergo anoikis—a form of apoptosis triggered by the 
loss of anchorage to substratum. Some of the signaling events in anoikis must be 
repressed in the carcinoma cells79,80. In addition, the tumour cells must overcome the 
damage incurred by the hemodynamic shear forces generated in the blood stream, and 
predation by cells of the innate immune system 63.   
 
1.4.4 Arrest and Extravasation 
Once lodged in the microvasculature of distant organs, the circulating tumour may 
form a microcolony that eventually causes the surrounding vessel to rupture, thereby 
placing tumour cells in contact with the tissue parenchyma 63,81. Alternatively, the 
carcinoma cells may once again cross the endothelium by undergoing TEM as outlined 
above. This may superficially resemble the steps of intravasation, but the process can in 
fact be quite a bit more challenging. During extravasation the carcinoma cells no longer 
have the co-opted tumour associated stroma to help provide signals, and the advantages 
provided by the tortuous and leaky neovasculature at the intravasation site are absent 63,81. 
 
1.4.5 Metastatic Colonization 
Once extravasated the carcinoma cells must survive in a foreign microenvironment, 
which can differ greatly from the site of the primary tumour formation. Differences may 
include the types of stromal cells, extracellular matrix constituents, available growth 
factors, cytokines, and even the microarchitecture of the tissue itself. For these reasons, 
the disseminated cancer cells are, at least initially, poorly adapted to their new 
surroundings. As a result, the tumour cells may suffer slow attrition over periods of 
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weeks and months, or persist as microcolonies in a state of long-term dormancy, neither 
gaining nor losing overall cell number 63,82. 
 
1.5 Targeting Metastasis  
Despite the natural barriers, challenges, and the high rates of attrition that accompany 
the steps of metastasis, overt metastases eventually do arise, and they almost invariably 
represent the source of terminal disease 63,70. The suppression of cancer metastasis is an 
urgent therapeutic need, yet most existing drugs inhibit only cancer cell proliferation 7-9. 
Therefore identifying therapeutic agent(s) that may target any of the various cell 
processes involved in metastasis will be crucial in reducing cancer mortality.  
 
1.6 Synthetic Triterpenoids 
1.6.1 Terpenes 
Terpenes are a large and diverse class of organic compounds that function as 
biosynthetic building blocks within nearly every living creature. Terpenes are derived 
from units of isoprene, which has the molecular formula C5H8, therefore the basic 
molecular formula for terpenes are multiples of (C5H8)n. This is known as the isoprene 
rule or the C5 rule. Terpenes may be classified by the number of isoprene units in the 
molecule, and a prefix in the name indicates the number of terpenes units needed to 
assemble the molecule. One single isoprene unit or C5 (hermiterpenes), C10 
(monoterpenes), C15 (sesquiterpenes), C20 (diterpenes), C25 (sesterpenes), C30 
(triterpenes), C40 (tetraterpenes), >C40 (polyterpenes) 83-86. Strictly speaking terpenes are 
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hydrocarbons, upon modification, oxidation, or addition of functional groups the terpene 
is then known as a terpenoid, therefore a C30 triterpene with functional groups would be 
called a triterpenoid. These terpenoids comprise the largest group of natural plant 
products, with over 20,000 known members 86,87. 
 
1.6.2 Triterpenoids and oleanolic acid 
Triterpenoids are formed through the cyclization of the 30-carbon squalene, and 
result in protostanes, lanostanes, holostanes, cycloartanes, dammaranes, euphanes, 
tirucallanes, tetranortriterpenoids, quassinoids, lupanes, oleananes, friedelanes, ursanes, 
hopanes, isomalabaricanes, and saponins. These triterpenoid carbon frameworks are 
cyclized by members of the oxidosqualene cyclase family, which has expanded greatly in 
plants 88.  
Oleanolic acid and its isomer ursolic acid are triterpenoid compounds that exist 
widely in plants, and have provided the basis of many traditional folk medicine due to 
their anti-inflammatory and hepatoprotective abilities. Studies on oleanolic acid 
confirmed that this triterpenoid does indeed have beneficial effects in numerous diseases, 
including chemically-induced liver injuries and cancer 89-93. However, these natural 
triterpenoids were found to have poor bioavailability and relatively weak biological 
activity, thus modification and synthetic versions of oleanolic acid have been made to 
improve on these shortcomings 94,95.   
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1.6.3 Synthetic Oleanane Triterpenoids 
More than 300 derivatives of oleanolic acid have been made by the Gribble 
laboratory (Dartmouth, USA, New Hampshire) and these molecules have been screened 
for their abilities to inhibit the de novo synthesis of the inflammatory enzyme nitric-oxide 
synthase (iNOS) 96,97. With the rationale being that inflammation is a causative factor for 
the pathogenesis of many human diseases, including cancer. Of the initial candidate 
screen, the 46th triterpenoid prepared (TP-46) in Gribble laboratory was identified as the 
first, “hit,” in their iNOS assay. Subsequent refinement and modification lead to the 
creation of TP-151 (“CDDO”) (2-cyano-3,12-dioxooleana- 1,9(11)-dien-28-oic acid), 
which was over 10,000 fold more potent than TP-46, and approximately 400,000 times 
more potent than oleanolic acid in their iNOS assay. Furthermore, it was found that by 
modifying the C-28 site on CDDO and replacing it with different functional groups, more 
potent synthetic oleanolic acid derivatives could be developed, two of which are CDDO-
Imidazolide (CDDO-Im) and CDDO-Methyl ester (CDDO-Me) (Figure 1.7A)96,97. 
As a group, these synthetic oleanane triterpenoids are multifunctional molecules 
in cell culture assays. In the nanomolar-to-micromolar range, they have been shown to 
suppress inflammation, activate cytoprotective pathways, induce differentiation, inhibit 
proliferation and induce apoptosis 95,97-103. 
 
1.7 Tricyclic Compounds 
During the development of CDDO, structure-activity studies revealed that the 2-
cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for high 
potency of CDDO. They reasoned that perhaps the entire oleanane skeleton might not be
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Figure 1.7 Synthetic oleanane triterpenoids and tricyclic compounds 
A) The base structure of the synthetic oleanolic acid derivatives, CDDO, CDDO-Im, and 
CDDO-Me. Highlighted in red are the enone moieties that contribute to the compounds 
extreme potency compared to oleanolic acid. 
B) The base structure for the acetylenic tricyclic bis-(cyano enone) compounds, TBE-31, 
TBE-55 and TBE-56. Note the similarity in rings A and C when compared to the 
synthetic oleanolic acid derivatives. 
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necessary for its potency, and therefore focused their attention on generating a new class 
of tricyclic compounds (tricyclic-bis-enone derivatives (TBEs)) which have the same A, 
B, and C rings of CDDO 104,105. In designing the tricyclic compounds, the medicinal 
chemists have aimed to avoid some of the limitations of the synthetic oleanane 
triterpenoids, in which only a single functional group at C-17 could be modified, and an 
expensive 11 step synthesis required to convert oleanolic acid into CDDO. In contrast, 
the TBEs could be entirely synthetic, and thus are not hindered by limited functional 
groups or by steric hindrance and the new compounds may have more structural 
diversity, better stability, enhanced pharmacokinetic and pharmacodynamics profiles 
compared to the synthetic oleanane triterpenoids 104-106. 
An early TBE-compound, TBE-9, was found to be nearly equivalent to CDDO in 
potency, both in in vitro assays inhibiting activity against production of nitric oxide by 
interferon-γ in mouse macrophages, and in in vivo studies using mouse peritoneal 
inflammation induced by thioglycollate and interferon-γ. 97,104,105. The design, synthesis 
and biological evaluation of new TBE analogues was continued by the Gribble 
laboratory. The acetylenic tricyclic bis-(cyano enone), TBE-31 [(±)-(4aα,8aα,10aβ)-
1,2,4a,6,8a,9,10,10a-octahydro-8a-ethynyl-1,1,4a-trimethyl-2,6-dioxophenanthrene-3,7-
dicarbonitrile], synthesized from cyclohexanone as a starting material, was again found to 
be significantly more potent than CDDO (Figure 1.7B)106,107. 
 
1.7.1.1 TBE-31 - The acetylenic tricyclic bis-(cyano enone) 
Since the compounds design and conception in 2007, TBE-31 has become an 
attractive candidate to be used as a lead compound. Different groups have assessed its 
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ability to suppress chronic inflammation, act as a chemopreventative agent and even its 
ability to serve as an anti-depressant 106. 
Liby et al. in 2008, showed that nanomolar concentrations of TBE-31 were able 
to suppress the induction of the inflammatory protein, iNOS, activate phase 2 
cytoprotective enzymes in vitro and in vivo, block cell proliferation, and induce 
differentiation of leukemia cells. When TBE-31 was orally administrated to rats, it 
significantly reduced formation of aflatoxin-DNA adducts, and decreased the size and 
number of aflatoxin-DNA preneoplastic hepatic lesions in rats by >90%. This work also 
suggested TBE-31 may interact with DTT and thus proteins that contain reactive cysteine 
residues, such as Keap1 108.  
The Keap1/Nrf2/ARE pathway regulates the ability of eukaryotic organisms to 
adapt and survive under various conditions of oxidative, electrophilic, and inflammatory 
stress by signaling the expression of a network of more than 100 genes, many of which 
encode for cytoprotective (“phase 2”) proteins. Under basal conditions, this pathway does 
not operate at its maximal capacity, but can be induced by a wide variety of different 
classes of small molecules. One universal property of these inducers is their capacity to 
modify sulfhydryl groups by alkylation, oxidoreduction or disulfide formation 109-111. 
Much of the work by Dinkova-Kostova and her and her group has focused on this 
pathway as a target for TBE-31. They demonstrated spectroscopically that both of the 
cyano enone functional groups of TBE-31 react with Keap1 and activate transcription of 
cytoprotective genes. By designing monocyclic compounds resembling fragmented rings 
A or C of TBE-31 (Figure 1.7B), they were able to demonstrate that ring C had a greater 
contribution as a Michael acceptor (i.e. greater ability to react with cysteines). Although, 
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most importantly, the presence of both rings held together in the configuration of TBE-31 
resulted in exceptionally high inducer potency towards the Keap1/Nrf2/ARE pathway 109.  
Further studies focused on in vivo applications of TBE-31 and the 
Keap1/Nrf2/ARE pathway. Long-term (five days per week for four weeks) topical 
applications of small (200 nM) quantities of TBE-31 were found to cause robust systemic 
induction of the Keap1/Nrf2/ARE pathway and decrease 6-ithoguanine nucleotide—
which is a metabolite of azathioprine, a highly effective anti-inflammatory and 
immunosuppressive agent used in organ transplantation and autoimmune disease, but 
which profoundly increases the risk for development of unusually aggressive cutaneous 
squamous cell carcinoma—incorporation in DNA of skin, blood, and liver of 
azathioprine-treated mice, indicating extraordinary bioavailability and efficacy. In 
addition, TBE-31 at nanomolar concentrations protected cells that do contain 6-
ithoguanine in their genomic DNA against oxidative stress caused by UVA radiation 
through the induction of the Keap1/Nrf2/ARE pathway. Thus, TBE-31 lowers two of the 
risk factors that contribute to the development of skin carcinogenesis associated with 
thiopurine therapies 112. This was confirmed in further experiments where the dosage of 
TBE-31 was also optimized. Topical TBE-31 (40 nmol/mouse, 2 days a week) was 
administered to mice while simultaneously administering azathioprine (1mg/kg/d in the 
drinking water) 2 weeks before starting an irradiation schedule, which consisted of 
chronic suberythemal solar simulated UV radiation (comprised of 2 J/cm2 UVA and 90 m 
J/cm2 UVB). After biweekly exposures for 15 weeks, irradiation was discontinued and 
tumour development was evaluated during the subsequent 16 weeks. TBE-31 was 
administered throughout these 31 weeks. The tumour incidences were not significantly 
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different between the control and the TBE-31 treated groups, but tumour multiplicity 
(tumour number) and tumour volume were all significantly lower. With the control group 
having 9.5 tumours per mouse with an overall average volume of 225 mm3 per mouse, 
compared to 5.3 tumours with an overall average volume of 41.9 mm3 per mouse for the 
TBE-31-treated group 113. In addition, in similar experiments the topical application of 
TBE-31 was shown to reduce the upregulation of 3 important inflammatory markers, IL6, 
IL1β and cyclooxygenase-2 by 55-, 24-, and 30% respectively, in the skin of UV 
radiation-induced inflammation in mice. This protective effect was largely absent in 
Nrf2-KO mice 113. Overall, Dinkova-Kostova and her group demonstrate that TBE-31 
effectively activate the Keap1/Nrf2/ARE pathway, reduce inflammation and reduce 
tumour burden. 
Other studies have explored TBE-31 and the Keap1/Nrf2/ARE outside of a 
chemopreventative context. Nrf2 activators have anti-depressant effects in animal models 
of depression. One study showed TBE-31 was able to potentiate nerve growth factor 
induced neurite outgrowth in PC12 cells in a concentration dependent manner. This effect 
was lost in Nrf2 siRNA treated cells. Furthermore, oral administration of TBE-31 to mice 
significantly attenuated an increase in serum levels of tumour necrosis factor-α (TNF-α) 
after administration of lipopolysaccharide (LPS). Lastly, in their LPS induced model of 
depression, they found TBE-31 to lower signs of depression in the tail suspension and 
forced swimming tests used to assess behaviour in mice. Therefore, TBE-31 may also be 
a potential therapeutic drug for inflammation-related depression 114. Aside from the 
Keap1/Nrf2/ARE pathway, TBE-31 has also been found to be able to upregulate Hsp70 
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in an HSF1-dependent manner in mouse embryonic fibroblasts (MEFs), and this has been 
shown to play a role in protection against peroxynitrite-induced cytotoxicity 115. 
The success of TBE-31 has prompted medicinal chemists to continue refining the 
process of generating TBE-31. Steps in the synthesis have been improved to increase the 
efficiency and yield of TBE-31 116,117. Moreover, a method for generating 13C215N2-
labeled TBE-31 and use in liquid chromatography-mass spectrometry (LC-MS) has been 
established, which will be useful for quantification of cell, tissue and plasma levels of 
TBE-31 118. Lastly, a biotin conjugated TBE-31 has been generated for use as a tool for 
the isolation of protein targets of TBE-31 (Figure 1.7B)119. 
 
1.8 CDDO-Im, CDDO-Me and cell migration 
Much of the current literature on the class of synthetic oleanolic acid derivatives 
and TBE-31 has been focused on their anti-inflammatory properties as outlined above. 
Although this is important work and has shown their potential use as chemopreventative 
agents through their anti-inflammatory properties, it has not address their effects on 
metastasis. Studies in the Di Guglielmo lab have begun exploring other important 
properties of these compounds, namely the cytoskeletal altering effects of the synthetic 
oleanolic acid derivatives and their effects on cell migration—an important component of 
metastasis. More specifically, CDDO-Im was found to alter microtubule dynamics by 
disrupting the microtubule capping protein, Clip-170. Microtubule-dependent processes 
were also altered, including the dispersal of EEA1-positive endosomes from the 
perinuclear region of CDDO-Im treated cells. Furthermore, CDDO-Im disrupted the 
localization of IQGAP1, PKCζ, Par6, and TGFβ receptors from the leading edge of 
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migrating cells and inhibited TGFβ-dependent cell migration (Figure 1.8A top)120. In 
addition, CDDO-Im and CDDO-Me were also found to associate with Arp3, a subunit of 
the Arp2/3 complex, which is necessary for branched actin polymerization and the 
formation of the lamellipodia in migrating cells. CDDO-Im and CDDO-Me were found 
to inhibit Arp3 localization at the leading edge, abrogate cell polarity, and inhibit Arp2/3-
dependent branched actin polymerization (Figure 1.8A bottom)121. The effects of CDDO-
Im and CDDO-Me on the microtubule network, cell polarity and  the actin cytoskeleton 
are all believed to contribute to inhibiting cell migration, thus making the synthetic 
triterpenoids potential anti-metastatic drugs 120,121. 
 
1.9 Rationale and Hypothesis 
Metastatic disease accounts for over 90% of cancer mortalities and there is an urgent 
need for therapeutic agents. Modulating or inhibiting any of the various steps that 
contributes to metastasis will greatly reduce incidences of cancer mortality. We have 
previously studied synthetic oleanolic acid derivatives for their abilities to impair cell 
migration—a process that is heavily utilized in multiple steps during the metastastatic 
cascade. The newer tricyclic compounds or TBEs resemble the synthetic oleanolic acids, 
and contain the same active regions responsible for their potency (Figure 1.8B). TBE-31 
has been demonstrated to be particularly potent in anti-inflammatory assays compared to 
the synthetic triterpenoids, but their effects on cell migration have not yet been studied. 
Given the structural similarities between the synthetic oleanolic derivatives and TBE-31, 
we hypothesize that TBE-31 will inhibit cell migration by targeting components of the 
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Figure 1.8 The effects of the synthetic oleanane triterpenoids and tricyclic 
compounds on cell migration 
A) A summary of the effects of CDDO-Im on cell migration. Top, CDDO-Im was found 
to alter microtubule dynamics by disrupting the microtubule capping protein, Clip-170, 
disrupt microtubule dynamics and organization, and cause a loss of polarity proteins to 
the leading edge. Bottom, CDDO-Im was found to inhibit Arp2/3-dependent branched 
actin polymerization at the leading edge. Note filopodia are unaffected as their formation 
is independent of Arp2/3. 
B) The effects of TBE-31 on cell migration are currently unknown.  
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 cytoskeleton. Therefore, we propose to examine the effects of TBE-31 on the 
components of the cytoskeleton necessary for cell migration. More specifically, we aim 
to: 
 
1) Characterize the effect(s) of TBE-31 on the actin cytoskeleton and cell 
migration. 
2) Characterize the effect(s) of TBE-31 on the structure and dynamics of the 
microtubule network and cell migration. 
3) Determine how TBE-31 interacts with actin. 
 
In doing so, we will broaden our understanding of the molecular biology of TBE-31 
and their role in cell migration and help advance the development of the tricyclic 
compounds and anti-metastatic agents in general.  
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2 Chapter 2  
2.1 Chapter Summary  
The migratory and invasive potential of the epithelial-derived tumour cells 
depends on epithelial-to-mesenchymal transition (EMT) as well as the reorganization of 
the cell cytoskeleton. Here we show that the tricyclic compound TBE-31 directly binds to 
actin and inhibits linear and branched actin polymerization in vitro.  Furthermore, we 
observed that TBE-31 inhibits stress fiber formation in fibroblasts as well as in non-small 
lung cancer cells during TGFβ-dependent EMT.  Interestingly, TBE-31 does not interfere 
with TGFβ-dependent signaling or changes in E-cadherin and N-cadherin protein levels 
during EMT. Finally, we observed that TBE-31 inhibits fibroblast and non-small cell 
lung tumour cell migration with an IC50 of 1.0 and 2.5 µM, respectively.  Taken together, 
our results suggest that TBE-31 targets linear actin polymerization to alter cell 
morphology and inhibit cell migration. 
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2.2 Introduction 
Cell migration is essential in numerous physiological processes such as 
embryogenesis, immune response, cell differentiation and cell renewal. However, it is 
also important in the later stages of cancer metastasis, where cell migration and invasion 
allow cancer cells to establish secondary tumour sites, which accounts for over 90% of 
cancer related deaths 1. 
Epithelial cells are normally non-motile, organized in an apical-basal polarity, and 
multiple cell-to-cell adhesions help assemble epithelial cells into a sheet-like formation 2-
5. In order for epithelial based tumours to detach from the primary tumour and migrate, 
the cells will have to dissociate these cell-to-cell contacts in a process known as the 
epithelial-to-mesenchymal transition (EMT) 2-5. These biochemical changes, among 
others, liberate the epithelial cells and enable them to assume a much more 
mesenchymal-like phenotype and prime them for cell migration and invasion 2-5.  
Cell migration begins with an initial protrusion of the cell membrane. Newly 
forming cell adhesions at the front attach the protrusions to the substratum and provide 
traction, while the focal adhesions at the rear disassemble and contractions help retract 
the tail. As this occurs repeatedly the cell translocates across the substratum 6-8. This 
process relies on the localization of polarity proteins and the reorganization of different 
components of the cytoskeleton, which consists of the microtubule network, intermediate 
filaments and the actin cytoskeleton. Although all the cytoskeletal components act in 
concert, it is the actin cytoskeleton that provides the force necessary for translocation. 
The localization of Rac1 or Cdc42 towards the leading edge with other polarity proteins 
is a key regulatory event that stimulates actin polymerization and results in membrane 
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protrusion towards the direction of migration. G-actin subunits polymerize to form actin 
filaments creating filopodia and lamellipodia. Cdc42 and formins regulate actin 
polymerization to form long unbranched bundles of actin to form filopodia, which are 
thought to act as sensors that can probe for external cues. Rac1 activates actin related 
proteins 2 and 3 (Arp2/3), causing it to bind to preexisting bundles of actin and promote 
branched actin polymerization to form lamellipodia, which are broad sheet like 
protrusions that drive the cell forwards 6-8. Bundles of actin also form stress fibers to give 
a cell its shape and work with focal adhesions and myosin to produce contractile forces in 
cell migration 9,10. Since EMT and cell migration are necessary processes for tumour cell 
metastasis, chemotherapeutic drugs that target various aspects of these processes are 
continuously sought.  
Triterpenoids are a family of naturally occurring compounds biologically 
synthesized in plants by the cyclization of squalene. They are a chemically diverse family 
with over 20,000 known compounds 11,12. Although oleanolic acid is of particular interest 
because of its anti-inflammatory and anti-tumourigenic properties, these potencies are 
relatively weak 11-14. Continuous synthetic modifications on oleanolic acid led to 2-
cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), which has much higher anti-
inflammatory and cytoprotective potency than oleanolic acid, as well as its imidazolide 
(CDDO-Im) and its methyl ester (CDDO-Me) 11-16. They have been demonstrated to 
effectively inhibit cytokines from inducing the formation of inducible nitric oxide 
synthase in macrophage cells and inducing phase 2 cytoprotective enzymes, both of 
which help prevent a cancer causing environment. In addition, they were found to inhibit 
proliferation, induce differentiation, and induce apoptosis in cancer cells in vitro. They 
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have also been shown to inhibit carcinogen induced primary tumour growth, orthotopic 
and ectopic tumour formation, as well as lung metastasis in multiple experimental animal 
models 11,12,17-22. 
Recently, we have observed that CDDO-Im and CDDO-Me have a number of 
effects on the cytoskeleton, leading to the interference of physiological processes that 
depend on them 23,24: CDDO-Im was observed to disrupt the microtubule network, 
displacing the polarity proteins IQGAP1 and Rac1 from the leading edge of migrating 
cells to abrogate cell polarity 23. Branched actin polymerization depends on the binding of 
actin related protein 2/3 (Arp2/3) to preexisting bundles of actin to provide a nucleation 
site and allow for branches of actin to polymerize, and CDDO-Im and CDDO-Me were 
both found to inhibit the actions of Arp2/3 24. Together these actions potently inhibit cell 
migration 23,24.  
Structure-activity studies on the parental pentacyclic compounds have revealed 
that the 2-cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for 
the potency of these compounds. Therefore new tricyclic compounds, termed tricyclic 
bis(enone) compounds (TBEs), were generated and which have great potential for 
structural diversity, robust pharmacokinetic and pharmacodynamic profiles 25-27.  In the 
pool of semisynthetic triterpenoids and synthetic TBEs, TBE-31 (Figure 2.1B) is one of 
the most potent compounds 25-27.  The oral administration of TBE-31 resulted in a 
profound and dose–dependent induction of the cytoprotective enzymes, 
NAD(P)H:quinone oxidoreductase 1 (NQO1) and glutathione S-transferases in the 
stomach, skin, and liver of mice, and indicated excellent oral bioavailability 28. Also, 
long-term topical daily applications of TBE-31 caused a robust systemic induction of the
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Figure 2.1 Chemical structures of pentacyclic triterpenoids and the acetylenic 
tricyclic bis-(cyano enone), TBE-31. 
A) The basic pentacyclic triterpenoid structure. CDDO-Im, which contains an 
imidazolide group, is used in this study. 
B) The acetylenic tricyclic bis-(cyano enone), TBE-31 and below is shown the 
biotinylated TBE-31, TBE-56. 
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Keap1/Nrf2/ARE pathway and decreased 6-thioguanine incorporation in DNA of skin, 
blood, and liver of azathioprine–treated mice, indicating extraordinary bioavailability and 
efficacy 29. Furthermore, TBE-31 is orally highly protective against aflatoxin–induced 
liver cancer in rats 30.   
To examine protein targets of TBE-31, a biotin conjugate of TBE-31, TBE-56, 
which is obtained from TBE-55, was designed and synthesized 31. In the present study, 
we investigated the effect(s) of TBE-31 on the actin cytoskeleton, and have determined 
that unlike the CDDO analogues, TBE-31 binds directly to actin to inhibit 
polymerization, and by doing so, TBE-31 also inhibits stress fiber formation during EMT 
as well as NSCLC tumour cell migration.  Therefore, TBE-31 is an exciting prospect for 
multi-targeted inhibition of metastatic potential. 
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2.3 Methods 
2.3.1 Cell Culture, Antibodies and Reagents 
Rat2 and NIH 3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM). A549 lung adenocarcinomas were cultured in Kaighn's Modification 
of Ham's F-12 Medium (F-12K) and H1299 human non-small cell lung carcinoma cells 
were cultured in Roswell Park Memorial Institute 1640 medium (RPMI-1640). All cells 
were cultured in a 37°C incubator with 5% CO2, and all media was supplemented with 
10% fetal bovine serum (FBS) unless otherwise stated. 
AlexaFluor 555 conjugated phalloidin (A34055) was purchased from Invitrogen. 
Anti-Smad2/3 (BD610843), anti-E-Cadherin (BD610182), anti-N-Cadherin (BD610921) 
and anti-Paxillin (BD610051) were purchased from BD transduction Laboratories 
(Mississauga, Ontario). Anti-Phospho-Smad 2 (AB3849) was purchased from Millipore. 
Cytochalasin D (C8273), Anti-Arp3 (A5979) was purchased from Sigma-Aldrich. 
NeutrAvidin Agarose beads (29200) was purchased from Thermo Scientific. Biotin 
Azide (PEG4 carboxamide-6-Azidohexanyl Biotin) (B10184) was purchased from Life 
Technologies. CDDO-Im and TBE-31 compounds were provided by Dr. Michael B. 
Sporn (Dartmouth, NH). The purified actin (AKL99), Arp2/3 (RP01), VCA domain of 
WASP (VCG03) and actin polymerization kits (BK003) were purchased from 
Cytoskeleton Inc.  
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2.3.2 Immunofluorescence microscopy 
In all immunofluorescence microscopy studies, cells were fixed in 4% 
paraformaldehyde for 10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in 
10% FBS, and immunostained overnight with the appropriate primary antibodies. All 
images were taken with an Olympus IX81 inverted epifluorescence microscope. 
 
2.3.3 Scratch Assays and Immunofluorescence Microscopy 
H1299 or NIH 3T3 cells were grown to confluence, and the monolayer was 
scratched with a pipette tip. DMSO, and varying concentrations of TBE-31 and CDDO-
Im were added to their appropriate media, and incubated at standard conditions. For 
scratch assays, bright field images were obtained at 0 h with an Olympus IX81 
microscope and the same coordinates were reimaged after 18 h (H1299 cells) or 12 h 
(NIH 3T3 cells). The extent of cell migration was measured by finding the difference in 
width of the scratch between 0 h and final time point. To generate videos, an Olympus 
IX81 inverted microscope was fitted with a custom chamber which allowed us to 
maintain a temperature of 37°C and an atmosphere containing 5% CO2. Bright field 
images were collected at regular 15 min intervals over the duration of the experiment. For 
immunofluorescence studies, Rat2 cells were scratched and given 4 h to polarize, before 
incubating in media containing DMSO, 1.0 µM of TBE-31, or 1.0 µM of CDDO-Im for 2 
h. The cells were then fixed, permeabilized and immunostained with anti-Arp3 antibody, 
phalloidin for filamentous actin, and DAPI for the nuclei. 
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2.3.4 Subconfluent Cell Migration 
Subconfluent NIH3T3 or H1299 cells were grown and treated with DMSO, 1 μM 
TBE-31 or 0.5 μM CDDO-Im. Time-lapse observations were made using an Olympus 
IX81 inverted microscope equipped with a custom chamber which allowed us to maintain 
a temperature of 37°C and an atmosphere containing 5% CO2. Bright field images were 
collected at 10 min intervals over 18 h. Distance of migration was determined by tracking 
the positions of cell nuclei over 18 h using the MtrackJ plugin 32  for imageJ software 33. 
 
2.3.5 In Vitro Actin Polymerization 
In vitro actin polymerization experiments were carried out using a modified 
version of the protocol supplied by Cytoskeleton Inc. Purified pyrene labeled actin was 
resuspended and incubated in general actin buffer provided by the Cytoskeleton Inc. for 1 
h on ice to depolymerize any actin oligomers followed by microcentrifugation at 4 °C for 
30 min. Two µM actin (Actin) or actin in the presence of 100 nM VCA domain of n-
WASp protein and 13 µM Arp2/3 complex (AVA) were incubated with DMSO, or 100 
µM of TBE-31 for 15 min on ice, before adding the actin polymerization buffer and 
warming the mixtures to 37°C to initiate polymerization. The change in fluorescence was 
measured with a Wallac Victor3 V plate reader. 
As a control, actin was fully polymerized in the absence of treatment (30 min) and 
the fluorescence intensity was measured. DMSO, 100 µM TBE-31 or 100 µM CDDO-Im 
was then added and the fluorescence intensity was immediately re-measured to ensure 
that these molecules do not interfere or quench the fluorescence intensity. 
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2.3.6 Actin Stress Fiber Repolymerization 
A subconfluent layer of NIH 3T3, H1299 or Rat2 cells grown on coverslips 
incubated in media containing 5 μM of cytochalasin D for 30 min at 37°C. Afterwards, 
the cells were rinsed with clean media to remove cytochalasin D, before reincubating in 
media containing either DMSO, 1 μM TBE-31, or 1 μM CDDO-Im. At various time 
points after reintroducing the new media, the cells were fixed permeabilized, and labeled 
for actin using AlexaFluor 555-conjugated phalloidin. 
 
2.3.7 Affinity Pull-downs 
Rat2 lysates incubated with DMSO, biotin, TBE-55, or TBE-56 at 4°C for 2 h, 
followed by incubating with NeutrAvidin beads for 1 h at 4°C to precipitate the proteins 
interacting with the biotin conjugate, TBE-56. Afterwards, the beads were thoroughly 
washed, and 2X Laemmli sample prep buffer was added. These samples were then 
subjected to SDS-PAGE, and silver staining was performed. Proteins that were uniquely 
stained in the TBE-56 samples were excised from the gel, trypsinized and analyzed by 
electrospray mass spectrometry. To confirm our results, the same pull-down experiments 
from above were performed with cell lysates or purified actin proteins, immunoblotting 
with anti-actin was performed after subjecting the samples to SDS-PAGE. For 
competitive binding studies, additional samples were added where TBE-31 or TBE-55 
were incubated with lysates 1 h before incubating with TBE-56, followed by the same 
steps as above. 
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2.3.8 Epithelial-to-mesenchymal transition 
A549 cells were incubated with 0.2% FBS F-12k media for 4 h, before the 
addition of 200 pM TGFβ was added for 48 h at 37°C to initiate an epithelial-to-
mesenchymal transition. For immunofluorescence studies the cells were grown on 
coverslips and fixed, permeabilized and immunostained with monoclonal paxillin 
antibody, and AlexaFluor 555 conjugated phalloidin for filamentous actin after the 48 h 
treatment. For western blot analysis, the cells were lysed, subjected to SDS-PAGE and 
immunoblotted for E-Cadherin, N-Cadherin, Smad2/3, Phospho-Smad2 or actin. 
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2.4 Results 
A hallmark of epithelial derived tumours is unregulated cell growth, and in many 
cases, the later stage of tumour progression is that cells undergo metastasis to migrate 
away from the primary tumour site and invade distant organs to establish secondary 
tumours 2,34-37. Therefore the development of chemotherapeutic agents that can inhibit 
different aspects of metastasis, including EMT and cell migration, will play a critical role 
in reducing in the rate of cancer mortality.  EMT and cell migration are dependent on the 
reorganization of the cytoskeleton, and the actin cytoskeleton has been proposed to be a 
feasible target in tumour metastasis 38. 
 
2.4.1 TBE-31 does not alter Arp3 localization in polarized cells 
Cell migration is dependent on the proper localization of proteins involved in 
maintaining cell polarity (for e.g., Cdc42/Rac1 and IQGAP1) as well as proteins involved 
in the formation of the lamellipodia via Arp2/3-dependent branched actin polymerization 
at the leading edge of migrating cells 6-8,39-41.  We previously demonstrated that CDDO-
Im displaces Arp2/3 from the leading edge, reduces branched actin polymerization and 
inhibits cell migration 23,24. TBE-31 contains a similar structural core as the pentacyclic 
triterpenoids (Figure 2.1) and has been shown to induce the Keap1/Nrf2/ARE pathway in 
a similar fashion as the pentacyclic compounds 28,29.  However, the effect(s) of TBE-31 
on the cytoskeleton remain unknown.  We therefore used immunofluorescence 
microscopy to examine if TBE-31 would target the cytoskeleton by first assessing if it 
targets the Arp2/3 complex and displaces it from the leading edge of migrating cells as 
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efficiently as CDDO-Im. Briefly, Rat2 fibroblasts were grown to confluence, scratched 
and allowed to polarize before being treated with DMSO, 1 μM TBE-31 or 1 μM CDDO-
Im. The cells were then immunostained for Arp3 and filamentous actin, followed by 
processing for immunofluorescence microscopy (Figure 2.2A).  We observed that 88 ± 
3% of the cells treated with DMSO exhibited Arp3 localization at the leading edge, while 
CDDO-Im reduced leading edge staining of Arp3 to 53 ± 18% (Figure 2.2), consistent 
with our previous observations 24. Interestingly, TBE-31 did not alter leading edge 
staining of Arp3 compared to the cells treated with vehicle (Figure 2.2).  This was 
intriguing because the core of the CDDO-Im molecule (similar to the TBE-31 core) was 
modeled to fit into the Arp3 inhibitory groove 24, similar to the bona fide Arp3 inhibitor, 
CK-869 42.  The lack of displacement of Arp3 from the leading edge in cells treated with 
TBE-31 suggests that the compound is not associating and interfering with the subcellular 
localization of Arp3. Therefore, in order to assess the binding of TBE-31 with Arp3 
and/or or other cytoskeletal proteins, we next carried out a pull-down approach. 
 
2.4.2 TBE-31 binds to actin directly 
To determine the binding partners for TBE-31, cell lysates were incubated with 
either DMSO or TBE-56, followed by precipitation with NeutrAvidin beads. Proteins 
associating with TBE-56 were separated on SDS-PAGE, processed and analyzed by mass 
spectrometry (Figure 2.3A). Although we previously used this approach to identify that 
CDDO-Me associated with Arp3 24, we were unable to detect an association between 
TBE-56 and Arp3.  The main cytoskeletal protein that was identified to associate with 
TBE-56 was actin and we further analyzed this interaction by immunoblot analysis 
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Figure 2.2 TBE-31 does not alter Arp3 localization to the cell periphery 
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in 
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were 
then incubated for 2 h in media containing DMSO, 1 µM CDDO-Im, or 1 µM TBE-31. 
The cells were then fixed, permeabilized and immunostained with Arp3 (green), 
AlexaFluor 555 phalloidin (red) for filamentous actin and DAPI (blue) for the nuclei. 
Shown here are representative immunofluorescence images taken with an Olympus IX81 
microscope at 40x magnification. Bar = 10 µm. The arrows highlight staining of Arp3 at 
the cell periphery. 
B) Experiments were carried out as described in panel A, quantitated and graphed for the 
number of  cells containing leading edge staining for Arp3 (n=3±SD, *p<0.05). 
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Figure 2.3 TBE-31 binds to actin 
A) Rat2 fibroblasts were incubated with either 10 µM biotin, TBE-55 or biotinylated-
TBE-31 (TBE-56), lysed, and incubated with NeutrAvidin-agarose beads. SDS-PAGE 
and silver staining were performed and proteins that were uniquely stained in TBE-56-
treated samples were excised from the gel, trypsinized, and analyzed by electrospray 
mass spectrometry.  Protein identifications are indicated on the right of the gel. Non-
specific binding labeled as NS. (n=3) 
B) Rat2 lysates or purified actin were incubated with either DMSO, TBE-55, or 
biotinylated-TBE-31 (TBE-56) at 4°C for 2h, followed by incubating with NeutrAvidin 
beads for 1h at 4°C to precipitate the proteins interacting with TBE-56. Afterwards, the 
beads were thoroughly washed, and sample prep buffer was added. These samples were 
then subjected to SDS-PAGE, followed by immunoblotting for actin. Shown here is a 
representative immunoblot (n=3). 
C) To perform competitive binding studies similar experiments were performed as 
described in Panel B. Additional samples were add that had been pretreated with 
increasing concentrations of TBE-31 or TBE-55, before incubating with biotinylated 
TBE-31 (TBE-56). Shown here is a representative immunoblot (n=3) 
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(Figure 2.3B).  Briefly, Rat2 lysates were incubated with DMSO, TBE-55 or TBE-56, 
precipitated with NeutrAvidin beads and processed for immunoblotting with actin 
antibodies and we observed that TBE-56 associated with actin in cell lysates (Figure 
2.3B, left panel).  In order to assess if this interaction was direct, we carried out the pull-
down assay using purified actin and observed similar results (Figure 2.3B, right panel), 
suggesting that TBE-56 does indeed bind directly to actin and not through an associated 
binding partner.  Furthermore, we performed competitive binding assays where Rat2 
lysates were pretreated with either DMSO, or increasing concentrations of TBE-31 or 
TBE-55, before incubating with TBE-56. We found that by increasing the concentrations 
of TBE-31 or TBE-55 in the pretreatment, actin was unable to be precipitated by the 
biotin conjugate, TBE-56 (Figure 2.3C). 
These results suggested that biotinylated TBE-31 is able to associate with actin 
but not Arp3. We next assessed if the tricyclic compound would have an effect on linear 
vs. actin polymerization in vitro. 
 
2.4.3 TBE-31 inhibits actin polymerization  
Actin is a globular multifunctional protein that binds end-to-end to form 
filaments, which can provide a basis for contractile forces, cell protrusions or structure 
6,7,9,10,43. We examined the effects of TBE-31 on actin dynamics by assessing in vitro 
polymerization of actin (Figure 2.4A). Briefly, purified pyrene labeled actin was 
incubated on ice to depolymerize any actin oligomers. Actin was incubated in the
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Figure 2.4 TBE-31 inhibits actin polymerization and stress fiber formation 
A) Purified pyrene-labeled actin was polymerized in the presence of DMSO (vehicle), 5 
μM cytochalasin D (Cyto. D; top panel), 100 μM CDDO-Im (middle panel) or 100 μM 
TBE-31 (bottom panel). For branched actin polymerization 100 nM VCA domain of n-
WASp protein and 13 μM Arp2/3 complex in addition to the Actin (AVA). Actin 
polymerization was measured by pyrene fluorescence and graphed as fluorescence 
intensity (arbitrary units) versus time (min). (n=3 ± SEM).  Note: All the conditions in 
the graphs were carried out together and the results are separated into three graphs for the 
sake of clarity.  The control conditions (gray lines) are shown in each graph to indicate 
the differences in vehicle vs. compound treated samples. 
B) To ascertain that the addition of TBE-31 or CDDO-Im would not quench pyrene-actin 
fluorescence intensity, pyrene actin polymerization was carried out as described in the 
Materials section, measured (-) and then DMSO, TBE-31 or CDDO-Im were added to the 
samples and re-measured (+) for fluorescence intensity.  Note that the fluorescence 
intensity did not appreciably change after vehicle or drug addition. 
C) A subconfluent layer of NIH 3T3 cells were grown on coverslips and incubated in 
DMEM supplemented with 5 μM cytochalasin D at 37°C for 30 min to depolymerize the 
actin cytoskeleton. Afterwards, the cells were rinsed with PBS to remove the previous 
treatments. Media supplemented with DMSO, 1 μM TBE-31, or 1 μM CDDO-Im was 
then reintroduced to the cells while the actin stress fibers repolymerized in the absence of 
cytochalasin D. The cells were then fixed, permeabilized and immunostained with 
AlexaFluor 555 phalloidin to visualize actin filaments (red), and DAPI (blue) for the 
nuclei. Shown here are representative immunofluorescence images taken with an 
Olympus IX81 microscope at 40x magnification (n=3). Bar=20 μm.   
D) Quantitation of cells with actin stress fibers (inset; white arrows) was carried and 
graphed (bottom panel; n=3± SEM, *p<0.05). Quantified cells were differentiated from 
cells containing cortical actin staining (inset; yellow arrowhead). 
E) A subconfluent layer of Rat2 fibroblasts were grown on coverslips and incubated in 
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media supplemented with 5 μM cytochalasin D at 37°C for 30 min to depolymerize the 
actin cytoskeleton. Afterwards, the cells were rinsed with PBS to remove the previous 
treatments. Media supplemented with DMSO, 1 μM TBE-31, or 1 μM CDDO-Im was 
then reintroduced to the cells while the actin stress fibers re-polymerized in the absence 
of cytochalasin D. The cells were then fixed, permeabilized and immunostained with 
AlexaFluor 555 phalloidin to visualize actin filaments (red), and DAPI (blue) for the 
nuclei. Shown here are representative immunofluorescence images taken with an 
Olympus IX81 microscope at 40x magnification (n=3). Bar=20 μm.  Inset: 
Representative areas were magnified to demonstrate actin stress fibers (white arrows) or 
areas of branched actin polymerization (blue arrowheads).  Note that TBE-31 treatment 
reduced the length of stress fibers but did not inhibit branched actin polymerization.  
However, CDDO-Im treated Rat2 fibroblasts contained actin stress fibers comparable to 
vehicle-treated cells but contained reduced branched actin polymerization. 
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presence of DMSO (vehicle), TBE-31, CDDO-Im or cytochalasin D (CD) for 15 min on 
ice, before adding the actin polymerization buffer and warming the mixtures to 37°C to 
initiate polymerization. To induce branched actin polymerization, Arp2/3, and the VCA 
domain of n-WASp was added in addition to the Actin (AVA). By recording the change 
in fluorescence intensity, we measured the rate of polymerization. cytochalasin D is a 
well-established mycotoxin that reversibly binds with globular actin monomers to prevent 
polymerization 44,45. As expected, cytochalasin D inhibited the rate of linear and branched 
actin polymerization (Figure 2.4A, top panel). CDDO-Im inhibited the Arp2/3 mediated 
branched actin polymerization and had little effect on the polymerization rate of linear 
actin (Figure 2.4A, middle panel). This was expected, as we have previously 
demonstrated that CDDO-Im only acts on Arp2/3 to inhibit Arp2/3 mediated branched 
actin polymerization 24. Interestingly, TBE-31 was able to inhibit both branched and 
linear actin polymerization (Figure 2.4A, bottom panel). Furthermore, TBE-31 also 
reduced the total overall amount of polymerized actin by approximately 40%, suggesting 
that unlike cytochalsin D, which is capable of depolymerizing filamentous actin, TBE-31 
may be sequestering monomeric actin and preventing it from being incorporated into 
growing filamentous actin fibers.  Finally, to ascertain that the addition of the tri- or 
penta-cyclic compounds was not interfering with the fluorescence of the pyrene actin in 
the assay, we allowed actin to fully polymerize and then incubated the polymerized actin 
in the presence or absence of DMSO (control) CDDO-Im or TBE-31 (Figure 2.4B).  We 
observed that the addition of the tri or penta-cyclic compounds did not quench the 
fluorescent signal. 
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Taken together, these results are intriguing because CDDO-Im and CDDO-Me 
were found to inhibit cell migration by blocking branched actin polymerization 24, 
however TBE-31 may affect cell migration by targeting general actin polymerization.  
We therefore next assessed the effect TBE-31 would have an effect to actin 
polymerization in cells.  
Actin polymerization in cell culture was also examined in parallel with our in 
vitro experiments by examining actin stress fiber formations in NIH 3T3 fibroblasts. 
Briefly, NIH 3T3 fibroblasts were incubated for 30 min in media containing cytochalasin 
D to completely depolymerize the actin stress fibers. Afterwards, cytochalasin D was 
removed and the cells were incubated in media containing DMSO, TBE-31, or CDDO-Im 
while the actin cytoskeleton re-polymerized. At various time points, the cells were fixed, 
permeabilized, and labeled for filamentous actin using phalloidin. Immediately after 
cytochalasin D treatment, actin filaments were completely depolymerized, causing the 
cells to round up and lose their polarized morphology (Figure 2.4C, top panel). However, 
after removing the cytochalasin D and incubating cells in the presence of DMSO or 
CDDO-Im, the actin re-polymerized and formed stress fibers. Interestingly, TBE-31-
treated cells did not reestablish elongated stress fibers (Figure 2.4C, top panel). Closer 
examination showed that only short, cortical stress fiber formation was occurring (Figure 
2.4C, inset). Quantitation of these cells for cells with actin stress fibers vs. cells without 
stress fibers supported our observations. By two hours DMSO, CDDO-Im, and TBE-31 
treated cells had 47 ± 1%, 40 ± 3% and 39 ± 5% of cells with stress fibers formed 
respectively (Figure 2.4D). By six hours DMSO and CDDO-Im treated cells had 69 ± 3 
% and 73 ± 2% recovery of stress fibers, while TBE-31 treated cells had lagged behind 
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with only 43 ± 4%.  Similar results were obtained using Rat2 fibroblasts (Figure 2.4E).  
These results further support the idea that TBE-31 inhibits actin polymerization and 
predict that stress fiber formation would be inhibited in tumour cells undergoing 
epithelial to mesenchymal transition. 
 
2.4.4 TBE-31 inhibits TGFβ-dependent actin stress fiber formation 
during epithelial-to-mesenchymal transitions  
During epithelial-to-mesenchymal transitions, the actin cytoskeleton rearranges 
from a cortical alignment associated with cell-cell junctions into actin stress fibers, which 
are associated with cell migration 3,5. We therefore investigated whether TBE-31 would 
have an effect on the actin-dependent changes that occur during EMT. Briefly, non-small 
cell lung cancer (NSCLC) A549 cells were incubated in serum-free medium or medium 
containing TGFβ for 48 h, and either DMSO or TBE-31.  Afterwards, the cells were 
fixed, permeabilized and immunostained with paxillin antibody and phalloidin to 
visualize filamentous actin. Under bright field microscopy we observed a cobble stone 
phenotype associated with epithelial cells in the cells that were not stimulated with TGFβ, 
regardless of the addition of DMSO or TBE-31 (data not shown). These cells only 
demonstrated cortical actin staining with little to no stress fibers, which is another 
characteristic of epithelial cells (Figure 2.5A). Conversely, the cells stimulated with 
TGFβ in the presence of DMSO demonstrated an elongated, and spindle like phenotype 
and under immunofluorescence microscopy these cells also demonstrated proper stress 
fiber formation (Figure 2.5A), all of which are associated with a more mesenchymal 
phenotype. TGFβ stimulation in the presence of TBE-31 resulted in less stress fiber
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Figure 2.5 TBE-31 inhibits TGFβ-dependent actin stress fiber formation during 
NSCLC tumour cell EMT 
A) Serum starved A549 cells, were incubated in the presence or absence of TGF and 
with DMSO or 1 µM TBE-31 for 48 h at 37°C. The cells were then fixed permeabilized 
and immunostained with monoclonal paxillin antibody (green), and AlexaFluor 555 
conjugated phalloidin (red) for filamentous actin. Shown here are representative 
immunofluorescence images at 40x magnification (n=3). Bar = 10 µm. Insets highlight 
area of interest and indicate actin stress fibers (white arrows) vs. cortical actin staining 
(yellow arrowhead). 
B) Serum starved A549 cells, were incubated in media supplemented with 200 pM TGFβ 
and either DMSO or 1 µM TBE-31 for 30 min at 37°C. Cells were lysed prior to TGFβ 
stimulation, and 0.5 h, 1.5 h and 4.5 h after stimulation. Lysates were subjected to SDS-
PAGE and immunoblotted for p-Smad2, and Smad2 (n=4). 
C) A549 cells were serum starved for 4 h, before incubating in media containing 200 pM 
TGFβ and either DMSO, 1 µM TBE-31, or varying concentrations of cytochalasin D for 
48 h. Cells were subsequently lysed, subjected to SDS-PAGE and immunoblotted for E-
Cadherin, N-Cadherin, or Actin (n=3). 
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 formation and elongation; instead they displayed the cobblestone phenotype associated 
with epithelial cells (Figure 2.5A). These results suggest that TBE-31 inhibits the actin 
related changes in EMT induced by TGFβ. 
In order to assess if the inhibition of actin stress fiber formation in the A549 cells 
was due to an inhibition of the EMT process, we examined TGFβ signal transduction by 
examining Smad2 phosphorylation to ensure TBE-31 was not interfering with TGFβ 
signaling. Briefly, A549 cells were serum starved for 4 h before treatment with DMSO, 
TBE-31 or varying concentrations of cytochalasin D for 30 min. Afterwards, TGFβ was 
added to the media and was allowed to incubate for another 30 min before being lysed, 
subjected to SDS-PAGE, and immunoblotted for P-Smad2, Smad2 and actin. We 
observed that regardless of the pharmacological treatment, TGFβ was able to induce the 
phosphorylation of Smad2, suggesting that none of our treatments affected the TGFβ 
signaling pathways (Figure 2.5B).  
To further verify proper TGFβ signaling, we examined other biochemical changes 
that mark EMT. E-cadherin is the major component of epithelial adherens junctions, 
which form a belt-like structure around the cells to tether adjacent cells into an immobile 
sheet-like formation. During EMT the expression of E-cadherin becomes down regulated, 
which liberates the cells from one another. Conversely the expression of N-Cadherin, an 
adhesion molecule associated with highly migratory mesenchymal cells, becomes up 
regulated. This is known as the cadherin switch and is a major hallmark of EMT 2-5. 
These changes were examined by treating A549 cells with TGFβ for 48 h in the presence 
or absence of DMSO, TBE-31 or cytochalasin D, subjected to SDS-PAGE and 
immunoblotted for E-Cadherin and N-Cadherin (Figure 2.5C). Regardless of treatment, 
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TGFβ stimulation led to a decrease in E-cadherin expression, while N-cadherin 
expression increased. This suggested that a proper cadherin switch was occurring in the 
presence of TGFβ in vehicle, TBE-31 or cytochalasin D-treated cells and further 
reconfirms that TBE-31 does not have an effect on TGFβ signaling, or gene transcription 
associated with EMT. 
 
2.4.5 TBE-31 inhibits cell migration 
We next focused our attention on cell migration, another actin-dependent process 
that follows EMT in metastasis. Actin polymerization provides the main driving force in 
cell migration, and we have previously shown that the triterpenoids CDDO-Im and 
CDDO-Me inhibit the Arp2/3 mediated branched actin polymerization by binding to 
Arp2/3 and decrease the rate of cell migration 24. Since we have demonstrated that TBE-
31 is able to bind to actin directly and modify its polymerization into stress fibers, we 
next assessed if it could inhibit cell migration as well. To assess this, we used H1299 
human non-small cell lung carcinoma cells as well as migrating fibroblasts (NIH 3T3 
cells), which exhibited robust migration in our scratch assays (Figure 2.6).  In brief, 
H1299 or NIH 3T3 cells were grown to confluence and scratched to stimulate migration. 
The cells were then incubated in either DMSO, or varying concentrations of TBE-31 or 
CDDO-Im. We observed that after 18 h, DMSO treated H1299 cells had migrated on 
average 432 ± 25  µm, whereas the NIH 3T3 cells had migrated 545 ± 30 µm after 12 h. 
Overall, TBE-31 or CDDO-Im treated cells demonstrated a dose-dependent decrease in 
cell migration (Figure 2.6A, graphs) (Video 2-1). More specifically, the IC50 of TBE-31 
for H1299 cells was found to be 2.5 µM and 1 µM for the NIH 3T3 cells.  
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Figure 2.6 TBE-31 inhibits NSCLC tumour cell migration 
A) Top panel; Confluent monolayers of H1299 lung tumour cells were scratched and 
incubated at 37°C in media containing either DMSO, 2 μM TBE-31 or 1 μM CDDO-Im 
for 18 h. Shown are representative bright field microscopy images taken with an 
Olympus IX81 microscope at 10x magnification at 0 and 18h post-incubation.  Bottom 
panel; Scratch assays were carried out as described above using varying concentrations of 
TBE-31 or CDDO-Im and the relative cell migration was quantitated using ImagePro 
software (n=4±SD). *P<0.05. 
B) Top panel; Confluent monolayers of NIH 3T3 fibroblasts were scratched and 
incubated as described in panel A. Shown are representative bright field microscopy 
images taken with an Olympus IX81 microscope at 10x magnification at 0 and 12h post-
incubation (n=3). Bottom panel; Scratch assays were carried out as described above using 
varying concentrations of TBE-31 or CDDO-Im and the relative cell migration was 
quantitated using ImagePro software (n=3±SD). *P<0.05. 
C) Subconfluent H1299 or NIH 3T3 cells were incubated with vehicle (DMSO), 1 µM 
TBE-31 or 0.5 µM TCDDO-Im and imaged over 18 hours.  Using Image J software, the 
tracking patterns of migrating single cells (multi-color plots) were measured and graphed. 
The average distance migrated by the H1299 or NIH 3T3 cells are shown on the right 
(n=3 ± SD). *P<0.05. 
Video 2.1. TBE-31 inhibits NSCLC tumour cell migration 
Confluent monolayers of H1299 lung tumour cells were scratched and incubated at 37°C 
in media containing either DMSO (top), 1 μM TBE-31 (middle) or 1 μM CDDO-Im 
(bottom) for 18 h. Representative bright field microscopy images were taken at 10x 
magnification every 15 min using an Olympus IX81 microscope to create a movie. 
Video 2.2. TBE-31 inhibits NIH 3T3 cell migration 
Single cell tracking of NIH 3T3 cells was carried out using time-lapse microscopy with 
an Olympus IX81 inverted microscope equipped with a custom chamber which allowed 
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us to maintain a temperature of 37°C and an atmosphere containing 5% CO2. Bright field 
images were collected at 10 min intervals over 18 h. Distance of migration was 
determined by tracking the positions of cell nuceli over 18 h using the MtrackJ plugin 
(32)  for imageJ software (33). 
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The IC50 for CDDO-Im was found to be approximately 1 µM, for both cell lines, similar 
to our previous results using Rat2 fibroblasts 24.  
To confirm that TBE-31 and CDDO-Im were indeed inhibiting the migration of 
both tumour and fibroblast cell lines, we carried out single cell tracking studies of H1299 
or NIH 3T3 cells (Figure 2.6B).  Briefly, subconfluent populations of cells were 
incubated with media containing vehicle (DMSO), CDDO-Im or TBE-31 and imaged for 
18 hours.  The migration tracks as well as the average distance travelled were calculated 
and graphed (Figure 2.6B). (Video 2-2).  Consistent with the scratch assays, we observed 
that both TBE-31 and CDDO-inhibited NIH 3T3 and H1299 cell migration at low 
micromolar concentrations.   
Overall, our results show that TBE-31 associates and inhibits actin 
polymerization, resulting in reduced tumour cell stress fiber formation and cell migration. 
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2.5 Discussion 
Although the overall effect of TBE-31 on cell migration are not dissimilar from 
CDDO-Im and CDDO-Me (the compounds it was derived from) the effects on actin 
polymerization are strikingly different:  CDDO-Im and CDDO-Me were shown to only 
inhibit Arp2/3 dependent branched actin polymerization and did not have an appreciable 
effect on linear actin polymerization 24. This CDDO-Im-dependent or CDDO-Me-
dependent inhibition of Arp2/3 activity or perhaps branched actin formation was also 
associated with an absence of polarity proteins at the leading edge of migrating cell. The 
differences in TBE-31 and CDDO compound in their abilities to target linear vs. 
branched actin polymerization may also effect polarity protein localization and activity 
and will be investigated in future studies. In addition, CDDO-Im demonstrated the ability 
to alter microtubule dynamics and organization 23. Future studies will also examine the 
effects of TBE-31 on the microtubule network and the possible impact it may have on 
microtubule-dependent processes such protein trafficking, cell signaling, cell division, 
mitosis, and cell migration.  
The enormous biological diversity of cancer has led to limited promise for therapies 
that target single signaling molecules. It has been suggested that strategic combinations 
of agents targeting against the most critical alterations in cancer will be needed, or simply 
the use of more unspecific agents that modulate several relevant targets simultaneously 
46,47. Not surprisingly, drug discovery has moved towards investigating multi-target drugs 
in the last decade, in a large part due to the development of cancer therapeutics 48-50. 
TBE-31 is an attractive compound for cancer prevention due to its antioxidative, anti-
inflammatory response capabilities by inducing the Keap1/Nrf2/ARE pathway 25-29, and 
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now inhibiting cell migration by targeting actin. The parallels and contrasts between 
TBE-31 and the CDDO analogs may lend well to combinational therapies with cytotoxic 
drugs. The possibility for these and other synergistic effects between TBE-31 and drugs 
already used in the clinic will provide us with future avenues of research. 
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The acetylenic tricyclic bis-(cyano enone), TBE-31, 
targets microtubule dynamics and cell polarity in 
migrating cells 
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3 Chapter 3 
3.1 Chapter Summary  
Cell migration is dependent on the microtubule network for structural support as 
well as for the proper delivery and positioning of polarity proteins at the leading edge of 
migrating cells.  Identification of drugs that target cytoskeletal-dependent cell migration 
and protein transport in polarized migrating cells is important for understanding the cell 
biology of normal and tumour cells and can lead to new therapeutic targets in disease 
processes. Here, we show that the tricyclic compound TBE-31 directly binds to tubulin 
and interferes with microtubule dynamics, as assessed by end binding 1 (EB1) live cell 
imaging. Interestingly, this interference is independent of in vitro tubulin polymerization.  
Using immunofluorescence microscopy, we also observed that TBE-31 interferes with 
the polarity of migratory cells: The polarity proteins Rac1, IQGAP and Tiam1 normally 
localized at the leading edge of DMSO-treated migrating cell, but were observed to be in 
multiple protrusions around the cell periphery of TBE-31-treated cells.  Finally, we 
observed that TBE-31 inhibits the migration of Rat2 fibroblasts with an IC50 of 0.75 µM.  
Taken together, our results suggest that the inhibition of cell migration by TBE-31 may 
result from the improper maintenance of cell polarity of migrating cells. 
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3.2 Introduction 
 Epithelial cells are normally organized with apical-basal polarity, and multiple 
cell-to-cell junctions and adhesions maintain the barrier function in non-motile sheet-like 
formations. During epithelial-to-mesenchymal transition (EMT), epithelial cells undergo 
changes in the signaling pattern that define cell shape 1-4. The cell-to-cell junctions and 
apical basal polarity are lost, the cytoskeleton reorganizes, and the overall motility of the 
cells is enhanced 1-4. EMT is an essential process during organ development as well as in 
wound healing. However, during cancer progression, EMT acts as a precursor event to 
metastasis, unmasking the migratory and invasive potential of the tumour cells. Like 
EMT, cell migration is necessary in normal physiological conditions, such as 
embryogenesis, immune response, and wound healing, but during cancer metastasis cell 
migration and invasion allow cancer cells to establish secondary tumour sites, which 
accounts for over 90% of cancer related deaths 5-10. 
Cell migration begins with an initial protrusion of the cell membrane at the 
leading edge of the cell. Nascent adhesions attach the protrusion to the substratum, while 
mature focal adhesions at the rear disassemble. This occurs repeatedly to translocate the 
cell across the substratum. These events rely on the dynamic nature and coordination 
between the actin cytoskeleton and the microtubule network 7-10. Tubulin heterodimers, 
formed by α and β subunits, polymerize to form microtubules, slender filamentous tubes 
that emanate from the microtubule-organizing center (MTOC). The microtubule network 
is highly dynamic, constantly polymerizing and depolymerizing, and is tightly regulated, 
both spatially and temporally 11. During cell migration the microtubule network 
reorganizes to establish a structural skeleton for front-rear polarity. Polarity proteins such 
105 
 
as Rac1 and Cdc42 are asymmetrically trafficked to the leading edge via Rab5 positive 
endosomal vesicles along microtubules 11-13. This stimulates the rearrangement of the 
actin cytoskeleton, and initiates polymerization to provide the membrane necessary for 
protrusion 7-10. Since cell migration is necessary for tumour cell metastasis and cancer 
progression, chemotherapeutic agents that target aspects of this process are continually 
sought.  
The semi-synthetic oleanane triterpenoids are a class of multifunctional 
compounds that were observed to inhibit cell migration by targeting microtubule 
dynamics as well as actin related protein 2/3 (Arp2/3)-dependent branched actin 
polymerization 14,15.  Analysis of these pentacyclic compounds identified that the 2-
cyano-1-en-3-one in ring A and a 9(11)-en-12-one in ring C are responsible for drug 
action (Figure 3.1A). Therefore new tricyclic compounds, termed tricyclic bis(enone) 
(TBE) compounds were generated.   TBEs have great potential for structural diversity as 
well as more robust pharmacokinetic and pharmacodynamic profiles 16-18.  Of these 
compounds, TBE-31 (Figure 3.1A) was shown to be most potent in in vitro anti-
inflammatory assays 16-18 and we previously determined that TBE-31 binds directly to 
actin to inhibit linear actin polymerization 19. TBE-31 inhibits stress fiber formation 
during EMT as well as non-small cell lung cancer tumour cell migration 19.  Interestingly, 
the mechanism(s) that TBE-31 utilizes to inhibit cell migration are distinct from the 
pentacyclic triterpenoids, despite having common predicted reactive rings 14,15,19.  
Therefore, the identification and understanding of which proteins associate and are 
modulated by TBE-31 will be of great benefit for developing anti-cancer agents. In the 
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present study, we investigated the effect(s) of TBE-31 on the dynamics of the 
microtubule network and the positioning of polarity proteins in migrating cells. 
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3.3 Materials and Methods 
3.3.1 Cell Culture, Antibodies and Reagents 
Rat2 fibroblasts were cultured in Dulbecco’s modified Eagle’s Medium (DMEM). 
Mv1Lu mink lung cells were cultured in minimal essential medium (MEM) 
supplemented with 1% non-essential amino acids (NEAA). Mv1Lu cells stably 
transfected with HA epitope-tagged TGFβ type II receptor (HAT cells) were cultured in 
MEM containing 1% non-essential amino acids and 0.3 mg/mL Hygromycin B 
(Invitrogen # 10687-010). All cells were cultured in a 37°C incubator with 5% CO2, and 
all media was supplemented with 10% fetal bovine serum (FBS) unless otherwise stated. 
Monoclonal anti-Rac1 (cat. # 610650) and anti-EEA1 (cat. # 610457) antibodies 
were purchased from BD Biosciences (Mississauga, Ontario). Polyclonal anti-IQGAP1 
(H-109; cat. # sc-10792), anti-HA (Y-11; cat. # sc-805), polyclonal anti-Tiam1 (cat. # sc-
872), and polyclonal anti-Rab 5 (FL-215; cat. # sc-28570) were purchased from Santa 
Cruz Technology (Santa Cruz, CA.). Monoclonal anti-tubulin (2.1, cat. # T-4026) was 
purchased from Sigma-Aldrich. Monoclonal anti-active Rac1-GTP (cat. # 26903) was 
purchased from New East Biosciences. Nocodazole and Paclitaxel were purchased from 
Sigma-Aldrich. NeutrAvidin Agarose beads were purchased from Thermo Scientific. 
Biotin Azide (PEG4 carboxamide-6-Azidohexanyl Biotin) (cat. # B10184) was purchased 
from Life Technologies. The tubulin polymerization kit (cat. # BK006P) and purified 
tubulin (cat. # T240) were purchased from Cytoskeleton Inc. TBE-31, CDDO-Im were 
used as previously described (16).  The biotinylated derivative of TBE-31 (TBE-56) and 
the non-biotinylated control (TBE-55) were synthesized as previously described (Figure 
3.1A) 20. 
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3.3.2 Affinity Pull-downs and Mass Spectrometry 
 Rat2 lysates were prepared by incubating cells with TNTE lysis buffer (150 mM 
NaCl, 0.5 % Triton X-100, 25 mM Tris-Cl [pH 7.4], 5 mM EDTA) for 30 min at 4 ˚C and 
centrifuged (15,000 gav) for 10 min to remove cellular debris.  The lysates were then 
incubated with 0.1% DMSO (vehicle control), 10 µM biotin, 10 µM TBE-55, or 10 µM 
TBE-56 at 4°C for 2 h, followed by incubating with NeutrAvidin beads for 1 h at 4°C to 
precipitate the proteins interacting with the biotin conjugate, TBE-56. Afterwards, the 
beads were thoroughly washed, and 2X Laemmli sample prep buffer was added. These 
samples were then subjected to SDS-PAGE, and silver staining was performed. Proteins 
that were uniquely stained in the TBE-56 samples were excised from the gel, trypsinized 
and analyzed by electrospray mass spectrometry using a Waters, Q-ToF Global mass 
spectrometer equipped with a Z-spray source and run in positive ion mode.  The peptides 
were identified using MASCOT software. To confirm our results, pull-down experiments 
were carried out as described above, using cell lysates or 1 µg purified tubulin, followed 
by immunoblotting with anti-tubulin (1:1000) antibodies. For competitive binding 
studies, additional samples were pre-incubated with TBE-31 or TBE-55 for 1 h before 
pull-down studies were performed. 
 
3.3.3 Subcellular Fractionation 
Fractions containing the cytoskeleton were separated from those containing 
detergent-solubilized membranes and cytosol by the method described by Contin et al 21. 
Briefly, Mv1Lu cells were incubated for 2 h in control medium or media containing 10 
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μM nocodazole, 1 μM TBE-31 or 1 µM CDDO-Im and then rinsed with microtubule 
stabilization buffer (90 mM Mes (pH 6.7), 1 mM EGTA, 1 mM MgCl2, 10% (v/v) 
glycerol) that had been preheated to 37 °C. Cells were then lysed with microtubule 
stabilization buffer containing 10 μM paclitaxel, 0.5% Triton X-100, and protease 
inhibitors for 4 min at 37 °C. The solubilized fractions were then collected. To collect the 
remaining cellular structures containing the cytoskeleton, SDS-PAGE sample buffer was 
added to the culture dishes. Following scraping and passaging through a syringe, the 
fractions containing the cytoskeleton were collected. To analyze the partitioning of 
cytoskeletal proteins, fractions containing the soluble proteins or the cytoskeleton were 
subjected to SDS-PAGE and immunblotted with monoclonal anti-tubulin (1:1000) 
antibody. 
 
3.3.4 Immunofluorescence Microscopy 
In all immunofluorescence studies, cells were fixed in 4% paraformaldehyde for 
10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in 10% FBS, and 
immunostained overnight with anti-Rac1 (1:100), anti-Tiam1 (1:100), anti-EEA1 (1:100) 
or anti-IQGAP (1:100) antibodies. Following incubation with Alexafluor-488 or -555 
labeled secondary antibodies (1:250 dilution) and DAPI staining, cells were imaged using 
an Olympus IX81 inverted epifluorescence microscope. 
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3.3.5 Leading Edge Immunofluorescence Microscopy 
For immunofluorescence studies examining proteins at the leading edge, Rat2 
fibroblasts were grown to confluence on glass coverslips, and scratched with a pipette tip. 
They were then allowed to elongate and polarize for 4 h, before incubating in media 
containing DMSO, 1.0 μM of TBE-31, or 1.0 μM of CDDO-Im for 2 h. The cells were 
then fixed, permeabilized and immunostained with the primary and secondary antibodies 
as described above. For experiments where cells were probed using TBE-56 (or the TBE-
55 control), the cells were left untreated before being fixed, permeabilized and 
immunostained with the appropriate primary antibodies. 
 
3.3.6 Scratch Assays  
Rat2 fibroblasts were grown to confluence, and the monolayer was scratched with 
a pipette tip. The cells were then incubated with DMSO (control) or varying 
concentrations of TBE-31 or CDDO-Im. An Olympus IX81 inverted microscope was 
fitted with a custom chamber maintaining a temperature of 37°C and an atmosphere 
containing 5% CO2. Bright-field images were collected over 16 h. The extent of cell 
migration was measured by finding the difference in width of the scratch at 0 time and 16 
h in triplicate. For washout and recovery experiments, the media was replaced with drug 
free media, and the cells were imaged for a further 24 h. 
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3.3.7 EB1 Movies 
Mv1Lu cells were transfected with GFP-tagged EB1 using PolyJet transfection 
reagent (100688) from FroggaBio as per the manufacturer’s protocol.  The cells were 
then incubated for 48 h before incubating them with media containing DMSO (control) or 
1 µM TBE-31.  The fluorescent EB1 “comets” were imaged in live cells using an 
Olympus IX81 microscope as described above and quantitated using the Fiji tracking tool 
for ImageJ 22.  EB1 comets (≥ 1000 comets/cell) were imaged and the distances travelled 
were quantitated from 10 cells/condition/experiment and graphed (N=3 ± SEM). 
 
3.3.8 TGFβ Receptor Endocytosis 
Receptor internalization studies were carried out as previously described 14,23. 
Briefly, HAT cells expressing HA-tagged TGFβ type II receptor (TβRII) were incubated 
with anti-HA antibody for 2 h at 4 °C, followed by Alexafluor-555 (1:500) secondary 
antibody. Cells were then washed and further incubated at 37 °C for 1 h with DMSO, 1 
μM TBE-31, or 1 μM CDDO-Im. Afterwards, the cells were fixed, permeabilized and 
immunostained with anti-EEA1, secondary antibodies and DAPI. 
 
3.3.9 In Vitro Tubulin Polymerization 
 In Vitro tubulin polymerization experiments were carried according to the 
standard protocols supplied by Cytoskeleton Inc. In brief, 2 mg/ml of purified tubulin 
was polymerized in the presence of either 10 µM TBE-31, 10 µM CDDO-Im, 3 µM 
taxol, or 3 µM nocodazole, diluted in the tubulin polymerization buffer provided by 
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Cytoskeleton Inc at 37°C 1h. The buffer contained a fluorescent reporter, which allowed 
us to measure the rate of polymerization by measuring the change in fluorescence with a 
Wallac Victor3 V plate reader (Perkin-Elmer). All samples were done in duplicates for 
each experiment.  
 
3.3.10 Statistical analysis 
All quantitation carried out in this study was analyzed using one-way ANOVA.  
Statistical significance (p<0.05) for all quantitation (n≥3 ± SEM) is indicated with an 
asterisk (*). 
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3.4 Results 
In situ invasion of epithelial tumour cells relies on processes such as EMT and 
cell migration 6,24-27. Therefore the development and characterization of chemotherapeutic 
compounds that target different steps of metastasis, and in particular cell migration, may 
play an important role in curtailing tumour-related death. We recently showed that the 
tricyclic compound, TBE-31, is capable of inhibiting actin polymerization 19, however, 
the mechanism(s) that this compound utilizes to inhibit cell migration has not been fully 
characterized.  We therefore set out identify TBE-binding proteins using various control 
and biotinylated tricyclic compounds (Figure 3.1A). 
 
3.4.1 TBE-31 binds to tubulin directly 
To identify TBE-56-binding proteins, we incubated cell lysates with biotin, a non-
biotinylated derivative of TBE-31, TBE-55 (control), or TBE-56 (a biotinylated 
derivative of TBE-55), followed by precipitation with NeutrAvidin beads (Figure 3.1B). 
The TBE-56-bound proteins were separated on SDS-PAGE, processed and analyzed by 
mass spectrometry (Figure 3.1B).  Although we previously identified several TBE-
binding proteins using this approach 19, this new analysis extended the identification of 
novel cytoskeletal binding partners, including myosin-9, alpha-actinin, zyxin, and 
vimentin (Figure 3.1C).  However, the largest number of peptides identified in the 
analysis corresponded to alpha and beta tubulin—the basic building blocks of 
microtubules.  This therefore led us to investigate this interaction in greater detail through 
immunoblotting analysis. Briefly, Rat2 lysates were incubated with DMSO, TBE-55 or
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Figure 3.1 Tricyclic compounds directly associate with tubulin 
A) Structures of the triterpenoid and tricyclic compounds used in the study. 
B) Rat2 fibroblast lysates were incubated with 10 µM biotin, TBE-55 or TBE-56 at 4°C 
for 2h, followed by incubating with NeutrAvidin beads for 1h at 4°C to precipitate the 
proteins interacting with TBE-56. SDS-PAGE and silver staining were performed and the 
bands that were uniquely stained in the TBE-56-precipitated sample were excised from 
the gel, trypsinized and analyzed by electrospray mass spectrometry. Dashes indicate the 
bands that were analyzed. 
C) Table of proteins identified to precipitate with TBE-56.  The predicted molecular 
mass, identification, protein coverage, and number of peptides that were present in the 
analysis are shown.  Note that tubulin was present in multiple bands from the analysis 
(indicated in boxes). 
D) Rat2 cell lysates (left panel) or purified tubulin protein (right panel) were incubated 
with 10 µM TBE-55 (control) or 10 µM TBE-56 (biotinylated TBE) at 4°C for 2h, 
followed by incubating with NeutrAvidin beads for 1h at 4°C to precipitate the proteins 
interacting with TBE-56. The beads were then washed, subjected to SDS-PAGE and 
immunoblotted with anti- beta (β) tubulin antibodies. The migration of tubulin is 
indicated on the left of each panel. 
E) Rat2 cell lysates were incubated with 0.1% DMSO (−), 10 µM biotin, 10 µM TBE-55 
(control) or 10 µM TBE-56 (biotinylated TBE) at 4 °C for 2 h, followed by incubating 
with NeutrAvidin beads for 1 h at 4 °C to precipitate proteins interacting with TBE-56. 
The beads were then washed, subjected to SDS-PAGE and immunoblotted with antibeta-
tubulin (α-beta-tubulin) or anti-EB1 (α-EB1) antibodies. The migration of tubulin or EB1 
is indicated on the left of each panel. 
F) Competitive binding studies were carried out similarly to the experiments described in 
Panel D. Additional samples were added that had been preincubated with the indicated 
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concentrations of TBE-31 or TBE-55, before incubating with TBE-56. Shown here is a 
representative immunoblot for tubulin. 
G) Purified tubulin (1 µg/ml) was incubated with 10 µM TBE-56 as described in panel A. 
Additional samples were added that had been preincubated with the indicated 
concentrations of biotin or TBE-31 before incubating with TBE-56. Shown here is a 
representative immunoblot for beta-tubulin. 
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TBE-56, precipitated with NeutrAvidin beads, processed for immunoblotting and probed 
with tubulin antibodies (Figure 3.1D). As expected, we observed that TBE-56 associated 
strongly with tubulin in cell lysates, whereas the negative TBE-55 control did not (Figure 
3.1D, left panel). To assure that the TBE-tubulin interaction was not occurring through a 
secondary protein (for example a microtubule +TIP protein) we repeated the experiment 
and immunoblotted the precipitated TBE-56 for the presence of the +TIP protein, EB1 
(Figure 3.1E).  We observed that tubulin, but not EB1, associated with TBE-56.  
Furthermore, we also assessed TBE-56 association with purified tubulin, and observed 
results similar to our cell lysate studies (Figure 3.1D, right panel), suggesting that the 
interaction between TBE-56 and tubulin is indeed direct and not through an intermediate 
binding partner. Finally, we carried out competitive binding assays to assess if the 
parental TBE-31 compound could compete with the TBE-56-tubulin interaction (Figure 
3.1F). Briefly, cell lysates were pretreated with either DMSO, or increasing 
concentrations of TBE-31 or TBE-55, before performing TBE-56 pull-downs. We found 
that by increasing the concentrations of TBE-31 or TBE-55 in the pretreatment, tubulin 
was hindered from precipitation by TBE-56 in a dose-dependent manner (Figure 3.1F), 
suggesting that TBE-31 itself is indeed able to associate with tubulin. To confirm that 
TBE-31 associates with tubulin directly, we repeated these experiments using purified 
tubulin and observed similar results (Figure 3.1G). Having found that tricyclic compound 
TBE-31 associates with tubulin, we next assessed if TBE-31 would have an effect on 
tubulin polymerization and/or the cellular microtubule network. 
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3.4.2 TBE-31 alters microtubule organization and dynamics 
We first investigated the ability of TBE-31 to inhibit tubulin polymerization in 
vitro (Figure 3.2A).  In the presence of either the vehicle (DMSO) or TBE-31, tubulin 
was able to fully polymerize within one hour of incubation.  That is, TBE-31 does not 
alter in vitro tubulin polymerization.  As positive and negative controls, we also assessed 
tubulin polymerization in the presence of either nocodazole or paclitaxel, bona fide 
depolymerizing and stabilizing agents, respectively. As expected, tubulin was unable to 
polymerize in the presence of nocodazole and the rate of polymerization was increased in 
the presence of paclitaxel (Figure 3.2A).  Finally, as another control, we assessed in vitro 
tubulin polymerization in the presence of the pentacyclic compound, CDDO-Im.  Since 
we had previously demonstrated that this compound interferes with microtubule 
dynamics in cells, we expected that CDDO-Im would alter in vitro tubulin 
polymerization (Figure 3.2A).  Interestingly, this did not occur (Figure 3.2A) and 
therefore raises the possibility that triterpenoid and/or tricyclic compounds may alter 
microtubule dynamics in cells but not via the rate of tubulin 
polymerization/depolymerization directly.  Thus, we attempted to assess the ability of 
TBE31 or CDDO-Im to alter tubulin depolymerization in cells. 
We assessed microtubule depolymerization by subcellular fractionation studies in 
drug treated cells by isolating the polymerized cytoskeleton from the soluble monomers 
14,21. After subjecting cytoskeletal or soluble fractions to SDS-PAGE and 
immunoblotting, we observed that tubulin remained in the polymerized cytoskeletal 
fractions in DMSO, CDDO-Im or TBE-31-treated cells (Figure 3.2B). However, when 
  
120 
 
Figure 3.2 TBE-31 inhibits microtubule dynamics independent of tubulin 
polymerization. 
A) Purified tubulin was polymerized in the presence of 10 µM TBE-31, 10 µM CDDO-
Im, 3 μM paclitaxel, or 3 μM nocodazole as described in Materials and Methods. Tubulin 
polymerization was measured and graphed as the change in fluorescence intensity 
(arbitrary units) over time (min). 
B) Mv1Lu cells were incubated in DMSO (vehicle), 1 µM TBE-31, 1 µM CDDO-Im, or 
10 µM nocodazole (Nocod.; positive control) for 2 h at 37°C and then subjected to lysis 
at 37 °C to separate soluble proteins (S) from the cytoskeleton (C). The subcellular 
fractions were then subjected to SDS-PAGE analysis followed by immunoblotting for 
tubulin. 
C) Subconfluent Mv1Lu cells were grown on coverslips and incubated in either DMSO, 
2 µM TBE-31, or 2 µM CDDO-Im for 2 h at 37°C. The cells were then fixed 
permeabilized and immunostained with monoclonal tubulin antibody (green) and DAPI 
(blue) for the nuclei. Shown here are representative immunofluorescence images taken 
with an Olympus IX81 microscope at 60x magnification. The insets highlight the 
organization of the microtubule network. Bar = 10 µm. 
D) Subconfluent Mv1Lu cells transiently expressing GFP-EB1 were incubated in either 
DMSO or 2 µM TBE-31 and imaged using an Olympus IX81 fluorescent microscope 
equipped with a cell chamber.  GFP-EB1 mobility was visualized over 2.5 min.  The 
starting point of EB1 comet movement (top panels) is shown.  Insets were magnified to 
visualize comet tail morphology (middle panels).  Comet tail migration over 2.5 min. was 
visualized (colored lines in bottom panels) and the track lengths were measured and 
graphed.  Shown are the mean ± SEM (n=3). Blue to red color bar represents shorter to 
longer tracks, respectively. 
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 cells were incubated with the microtubule-depolymerizing agent, nocodazole, the 
majority of the tubulin segregated with the soluble cellular components (Figure 3.2B).  
Although these results were consistent with the in vitro assays, we continued our analysis 
of TBE-31 or CDDO-Im on microtubule dynamics because of the crucial role that the 
microtubule network plays in cell migration by providing a cellular structure as well as a 
network for vesicular trafficking 7,8,11.  
We examined the cellular microtubule network by assessing the general 
morphology using immunofluorescence microscopy. Briefly, Mv1Lu cells were treated 
with DMSO, TBE-31, or CDDO-Im, and immunostained with a tubulin antibody to 
visualize the microtubule network. In the DMSO-treated cells, microtubules emanated 
from the microtubule-organizing center (MTOC) in a straight and linear fashion, while 
the CDDO-Im demonstrated a high degree of curvature and a tortuous pattern, which is 
consistent with our previous findings (14; Figure 3.2C). Interestingly, the microtubule 
organization in TBE-31 treated cells was observed to be in a crosshatched pattern, that 
was distinct from DMSO and CDDO-Im treated cells (Figure 3.2C).  Together these 
results suggest that TBE-31 alters the organization of the microtubule network, but not 
necessarily the rates of growth or retraction. We furthered our investigation by next 
examining microtubule-dependent dynamics. 
End binding protein 1 (EB1) localizes to the microtubule plus ends where it 
modulates their dynamics and interaction with organelles 11,28,29. We assessed the rate of 
microtubule growth as well as the microtubule persistence by transfecting GFP tagged 
EB1 in Mv1Lu cells and visualizing them over time to observe microtubule dynamics in 
the presence of our compounds (Figure 3.2D). In DMSO treated control cells, we 
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observed that EB1-labeled ends of growing microtubules gave the appearance of rapidly 
growing oval (longer tail) comet-like streaks that radiated outwards smoothly from the 
MTOC in an organized and structured manner (Figure 3.2D; Video 3-1). However, TBE-
31 treated cells demonstrated shorter, rounded comet-like streaks, consistent with slower 
growing microtubules 30.  Furthermore, close examination of movies gave the appearance 
of multiple MTOCs in TBE-31 treated cells, whereas a single major MTOC was observed 
in control cells. This multi-MTOC and overall less organized movement pattern was 
consistent with the cross-hatched microtubule pattern demonstrated in the 
immunofluorescence microscopy analysis (Figure 3.2D; Video 3-2). To confirm that  the 
EB1 tracks were less organized in the TBE-31-treated cells we carried out quantitation 
and observed that the EB1 tracks in DMSO treated cells averaged 8.5± 1 µm/track, 
whereas TBE-31-treated cells contained significantly shorter EB1 tracks, averaging 5.8 ± 
0.6 µm/track (Figure 3.2D, bottom graph).  
 
3.4.3 TBE-31 disrupts microtubule-dependent trafficking 
Having shown that TBE-31 affects microtubule organization and dynamics, we 
sought to investigate processes that are dependent on proper microtubule function; the 
positioning of the early endosome compartment to the peri-nuclear region of the cell. In 
brief, Mv1Lu cells were incubated in media containing DMSO, 1 μM TBE-31, or 1 μM 
CDDO-Im for 2h at 37°C. The cells were then immunostained with early endosome 
antigen 1 (EEA1) antibody for the early endosome and DAPI for the nuclei (Figure 
3.3A). We then scored the number of cells that demonstrate a peri-nuclear staining
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Video 3-1 and 3-2 EB-1 Movies 
Subconfluent Mv1Lu cells transiently expressing GFP-EB1 were incubated in either 
DMSO or 2 µM TBE-31 and imaged using an Olympus IX81 fluorescent microscope 
equipped with a cell chamber.  GFP-EB1 mobility was visualized over 2.5 min.   
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Figure 3.3 TBE-31 affects trafficking and cellular distribution of EEA1-positive 
endosomes 
A) Subconfluent Mv1Lu cells were grown on coverslips and incubated in DMSO, 1 µM 
TBE-31, or 1 µM CDDO-Im for 2 h at 37°C. The cells were then fixed permeabilized and 
immunostained with EEA1 antibody (green) for the early endosome and DAPI (blue) for 
the nuclei. Shown here are representative immunofluorescence images taken with an 
Olympus IX81 microscope at 60x magnification. The insets highlight the early endosome 
compartments. Bar = 10 µm. 
B) Immunofluorescence microscopy was carried out as described in panel A and the 
number of cells with peri-nuclear EEA1 staining was quantitated and graphed.  Shown 
are the mean ± SEM (n=3; * P≤0.05).  
C) Mv1Lu cells stably expressing HA-tagged type II TGFβ receptors (TβRII) were 
incubated at 4 °C with anti-HA antibodies, followed by Alexa555-labelled secondary 
antibodies (red). The cells were then incubated at 37 °C in the absence (top panel; 
Control) or presence of 1 µM TBE-31 (middle panel) or 1 µM CDDO-Im (bottom panel) 
for 1 h. Cells were then fixed, permeabilized, and immunostained with anti-EEA1 
(EEA1; green) antibodies. Areas of interest (insets) are magnified and are shown below 
each panel. The contour (dotted line) of each cell was added to indicate the relative 
position of TβRII and EEA1 from the cell periphery. Bar = 10 µm. 
D) Immunofluorescence microscopy was carried out as described in panel C and the 
number of cells with peri-nuclear TGFβ receptor staining was quantitated and graphed.  
Shown are the mean ± SEM (n=3; * P≤0.05). 
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pattern versus cells with a dispersed EEA1 staining pattern. In the DMSO treated cells 
80.7 ±1.0% of the cells displayed peri-nuclear staining, whereas TBE-31 and CDDO-Im 
treated cells displayed only 60.3 ±1.3% and 39.4 ±0.6% peri-nuclear staining, 
respectively (Figure 3.3B).  We next examined what implications this may have on 
endocytosis and protein trafficking. To do so, we used the well-characterized 
transforming growth factor beta (TGFβ) receptor (TGFβR) model that utilizes 
microtubules to deliver TGFβRs to the early endosome 31. 
Cell surface TGFβRs, undergo endocytosis and traffic to the early endosome 
where they can interact and phosphorylate Smad proteins to propagate TGFβ signaling 
23,32,33. To evaluate the ability of TGFβR microtubule-dependent trafficking to the early 
endosome, we used an immunofluorescence microscopy based approach. Briefly, cells 
stably expressing HA-tagged type II TGFβR (TβRII) were treated with DMSO, TBE-31 
and CDDO-Im and then incubated at 4°C to inhibit endocytosis and to allow the labeling 
of cell surface receptors. The cells were then incubated at 37°C which reinitiated receptor 
endocytosis and trafficking to the early endosome. We then performed standard 
immunofluorescence microscopy and probed for EEA1 to visualize the early endosome 
in addition to the previously labeled TGFβR. We observed that TGFβRs in vehicle 
(DMSO)-treated cells internalized and co-localized to EEA1-positive vesicles in the peri-
nuclear region of the cell (Figure 3.3C).  Interestingly, TBE-31 or CDDO-Im cells 
demonstrated less peri-nuclear trafficking of TGFβRs, however the receptors still co-
localized with EEA1-positive vesicles near the cell periphery (Figure 3.3D).  Taken 
together, our results suggest that TBE-31 alters microtubule dynamics, and impairs 
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protein trafficking—two processes that are important in cell polarity and migration 7-11. 
As such, we next sought to explore the effects of TBE-31 on these processes. 
 
3.4.4 TBE-31 alters front-rear polarity in migrating cells 
Cell migration is dependent on the proper localization of proteins involved in 
maintaining cell polarity (for e.g., Rac1 and IQGAP1) 8-10,34-36, which are dependent on 
early endosome trafficking (Rab5 positive vesicles for Rac1) 11-13. We previously 
demonstrated that CDDO-Im displaces IQGAP1, and Rac1 from the leading edge of 
migrating Rat2 fibroblasts and inhibits cell migration 14,15. Here we examined if the 
effects of TBE-31 on the microtubule network and protein trafficking would also lead to 
impaired cell polarity. Delivery of Rac1 has been shown to be dependent on Rab5 
function, so Rab5 vesicles were examined in a similar manner as our analysis of the 
EEA1 compartment.  However, Rab5 distribution in TBE-31-treated cells was similar to 
that of control cells (treated with DMSO), while CDDO-Im treated cells did exhibit a 
higher degree of Rab5 vesicle placement near the cell periphery (Figure 3.4). 
We next examined the localization of IQGAP1 and Rac1 in migrating cells 
(Figure 3.5). Briefly, Rat2 fibroblasts were grown to confluence before an artificial 
wound was introduced by scratching the cells. The cells were allowed to polarize for 4h 
before being treated with DMSO, TBE-31 or CDDO-Im. Following immunostaining for 
IQGAP1 and Rac1, the cells were processed for immunofluorescence microscopy (Figure 
3.5A). We observed that 66.9 ± 5.8% of the cells treated with DMSO were elongated and 
had IQGAP staining at the leading edge—a phenotype indicative of proper polarization
133 
 
Figure 3.4 TBE-31 does not affect cellular distribution of Rab5-positive endosomes 
Subconfluent Mv1Lu cells were grown on coverslips and incubated in 0.1% DMSO, 1 
µM TBE-31, or 1 µM CDDO-Im for 2 h at 37°C. The cells were then fixed permeabilized 
and immunostained with Rab5 antibody (green) for the early endosome and DAPI (blue) 
for the nuclei. Shown here are representative immunofluorescence images taken with an 
Olympus IX81 microscope at 60x magnification. The insets highlight the early endosome 
compartments. Bar = 10 µm. 
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Figure 3.5 TBE-31 alters cell polarity 
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in 
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were 
then incubated for 2 h in media containing DMSO, 1 µM TBE-31, or 1 µM CDDO-Im.  
The cells were then fixed, permeabilized and immunostained with monoclonal Rac1 
antibody (green), polyclonal IQGAP1 antibody (red) and DAPI (blue) for the nuclei. 
Shown here are representative immunofluorescence images taken with an Olympus IX81 
microscope at 40x magnification. Bar = 10 µm. 
 
B) Immunofluorescence microscopy was carried out as described in panel A and the 
number of cells containing an elongated morphology and one IQGAP1-positive leading 
edge, cells containing multiple IQGAP1-positive protrusions or cells lacking IQGAP1 
staining at the cell surface were quantitated and graphed. Shown are the mean ± SEM 
(n=3; * P≤0.05).  
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 and migration. In contrast, only 36.1 ± 4.1% of CDDO-Im-treated cells demonstrated 
proper polarization (Figure 3.5B).  Furthermore, the majority, 49.7 ± 1.0 %, of CDDO-
Im-treated cells showed no elongation, as well as an absence of IQGAP1 from the 
leading edge, which is consistent with our previous findings 14. TBE-31 was also 
observed to affect polarity, with only 42.0 ± 5.3% of cells showing IQGAP1 localization 
at the leading edge. Interestingly, unlike CDDO-Im or DMSO treated cells, TBE-31 
treated cells exhibited IQGAP1 localization at multiple areas around the cell periphery, 
causing the formation of multiple protrusions in 43.5 ± 2.5% of cells (Figure 3.5B). 
The observation that TBE-31 induced multiple Rac1/IQGAP-positive protrusions 
in cells prompted us to investigate whether these protrusions contained active Rac1.  We 
therefore examined the multiple protrusions in the TBE-31 cells using an active-Rac1 
antibody that only recognizes Rac1 when it is in its GTP-bound form (Figure 3.6A) The 
experimental design was similar to the one described above: A monolayer of cells were 
scratched and allowed to polarize before treating with various compounds. The cells were 
then immunostained with Rac1 and anti-active Rac1-GTP. In the DMSO control, Rac1 at 
the single protrusions co-localized with active-Rac1-GTP. Interestingly, TBE-31-induced 
multiple protrusions contained active (GTP-bound) Rac1 (Figure 3.6B), thus confirming 
that the Rac1 was indeed active in multiple regions of TBE-31 treated cells. To further 
confirm that cellular regions that were labeled with the active-Rac1 antibody indeed 
contained GTP-bound Rac1, we further analyzed if there was the Rac1 activator, Tiam1, 
co-localization (Figure 3.6B).  Indeed, we found co-localization of Tiam1 and active-
Rac1 in single protrusions of control cells, multiple protrusions in TBE-31 treated  
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Figure 3.6 TBE-31 redistributes Rac1 activity to multiple areas of the plasma 
membrane 
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in 
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were 
then incubated for 2 h in media containing 0.1% DMSO, 1 µM TBE-31, or 1 µM CDDO-
Im.  The cells were then fixed, permeabilized and immunostained with an antibody that 
recognizes GTP-bound Rac1 (Active-Rac1; green), a Rac1 antibody (Rac1; red) and 
DAPI (blue) for the nuclei. Shown are representative immunofluorescence images.  Areas 
of interest (insets) are magnified and are shown below each panel. Bar = 10 µm. 
 
B) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in 
DMEM supplemented with 10% FBS for 4 hours to allow them to polarize. Cells were 
then incubated for 2 h in media containing DMSO, 1 µM TBE-31, or 1 µM CDDO-Im.  
The cells were then fixed, permeabilized and immunostained with a polyclonal antibody 
that recognizes GTP-bound Rac1 (Active-Rac1; green), a monoclonal Tiam1 antibody 
(Tiam1; red) and DAPI (blue) for the nuclei. Shown are representative 
immunofluorescence images.  Areas of interest (insets) are magnified and are shown 
below each panel. Bar = 10 µm. 
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cells, and a lack of membrane localization in CDDO-Im-treated cells (Figure 3.6B). 
Taken together, our results suggest that TBE-31 can disrupt the front-rear polarity in 
migrating fibroblasts, in a manner distinct from CDDO-Im. TBE-31 induces the 
formation of multiple protrusions that contain active Rac1, whereas CDDO-Im reduces 
active Rac1 localization at the membrane. 
 
3.4.5 TBE-31 inhibits cell migration 
A single dominant leading edge is associated with directionally persistent intrinsic 
cell migration, and enhanced directed cell migration 37. Therefore multiple protruding 
lamellipodia may result in random intrinsic migration and reduce the capacity for directed 
cell migration. We therefore next sought to examine the effects of TBE-31 on directed 
cell migration. In brief, a confluent monolayer of Rat2 fibroblasts was scratched and 
incubated in media containing either DMSO, varying concentrations of TBE-31, or 
CDDO-Im. Bright-field images were taken with an inverted microscope at 0 h and 16 h.  
The initial and final width of the scratch was measured, and the difference was calculated 
to determine the distance migrated. We observed that with increasing concentrations of 
TBE-31 or CDDO-Im the distance of migration decreased in a dose-dependent manner 
(Figure 3.7A). More specifically, quantitation demonstrated that both compounds 
exhibited similar inhibition of cell migration and above 0.75 μM, TBE-31 and CDDO-Im 
were able to reduce cell migration by approximately 60.0 ± 7.7% and 86.0 ± 2.6% 
percent, respectively (Figure 3.7B). CDDO-Im and TBE-31 have been previously shown 
to induce apoptosis, albeit at higher concentrations 38. In order to assess if the decrease in 
cell migration may be due to possible cytotoxic effects, we performed trypan blue
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Figure 3.7 TBE-31 inhibits cell migration. 
A) Confluent monolayers of Rat2 fibroblasts were scratched and incubated at 37°C in 
DMEM supplemented with 10% FBS, containing either DMSO, 1 μM TBE-31 or 1 μM 
CDDO-Im for 16 h. Shown are representative brightfield microscopy images taken with 
an Olympus IX81 microscope at 10x magnification at 0 and 16 h post-incubation. 
B) Scratch assays were carried out as described in panel A with cells incubated with 
increasing concentrations of TBE-31 or CDDO-Im. Relative cell migration was 
quantitated using ImagePro software and graphed.  Shown are the mean ± SEM (n=3; 
*=P≤0.05). 
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exclusion tests. We found that TBE-31 nor CDDO-Im was cytotoxic up to concentrations 
of 1.0 µM in Rat2 fibroblasts (data not shown).  Furthermore, wash out studies indicated 
that cells recover from CDDO-Im or TBE-31 incubation to fill in the gap (data not 
shown). 
Taken together, our results suggest that TBE-31 targets the microtubule cytoskeleton 
and establishes multiple leading edges around migrating cells, which leads to decreased 
cell migration.  
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3.5 Discussion 
We have previously demonstrated that TBE-31 targets linear actin polymerization to 
alter cell morphology and inhibit cell migration 19. In this study we continued to examine 
the effects of TBE-31 on cell migration with a focus on the microtubule network and 
observed that TBE-31 binds to tubulin directly and disturbs the dynamics of the 
microtubule network. Identifying the potential binding sites of TBE-31 on tubulin will 
allow for the characterization of how this class of compound inhibits microtubule 
dynamics. Based on previous studies, the interaction of triterpenoid and tricyclic 
compounds with target proteins has been shown to occur via association with reactive 
cysteine residues 38-42. We are currently assessing if this is the case of TBE-31 binding to 
tubulin. Furthermore, studying the impact of TBE-31 on different microtubule-dependent 
trafficking processes will be of great interest. Indeed, endocytosis and recycling play an 
important role in the regulation of integrin turnover and redistribution—especially during 
dynamic processes such as cell migration and invasion. The way in which focal adhesion 
proteins are trafficked is also recognized to influence their function and dictate the 
polarized distribution 43,44. Finally, the multiple leading edges visualized in TBE-31-
treated cells begs the question if the effects are global or local. Is cell polarity preserved 
and/or is there a defect in control of number of projections, without necessarily 
eliminating polarity?  Addressing these questions will help identify the different 
mechanisms that these chemopreventative multi-target drugs use to inhibit cell migration.
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Chapter 4  
 
 
 
 
Acetylenic tricyclic bis-(cyano enone) interacts with 
actin through cysteine-374 to interfere with actin 
polymerization 
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4 Chapter 4 
4.1 Chapter Summary 
The migratory and invasive potential of tumour cells relies on the actin cytoskeleton. 
In the past we have demonstrated TBE-31 inhibits actin polymerization and here we 
further examine the exact binding between TBE-31 and actin. We demonstrate that 
iodoacetamide, a cysteine (Cys) alkylating agent, interferes with the ability of TBE-31 to 
interact with actin. In addition, computational analysis identified Cys 217, Cys 272, Cys 
285 and Cys 374 as potential TBE-31 binding sites. Using mass spectrometry analysis we 
determined 1 molecule of TBE-31 binds with 1 molecule of actin. We mutated the 
cysteines of actin to alanine and performed a pull-down analysis with a biotin labeled 
TBE-31 and demonstrated that by mutating Cys 374 to Alanine the pull-down 
significantly decreased association between TBE-31 and actin, suggesting that TBE-31 
binds to Cys 374. A characterization of the eGFP-C374A-Actin in NIH3T3 cells showed 
reduced stress fiber formation, suggesting Cys 374 is necessary for efficient 
polymerization or incorporation into filamentous actin. Lastly, transwell migration assays 
were conducted with NIH3T3 cells, and the number of cells that migrated through the 
transwells was significantly reduced. Taken together or results suggest TBE-31 binds to 
Cys 374 of actin to inhibit actin polymerization and may potentially be the mechanism 
wherein TBE-31 utilizes to inhibits cell migration. 
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4.2 Introduction 
Cell migration is essential for numerous physiological processes such as 
embryogenesis, immune response, cell differentiation, wound healing, and cell renewal. 
However, it is also co-opted in the later stages of cancer 1-3. During metastasis, tumour 
cell migration and invasion are exploited to allow cells to disseminate to distant sites and 
establish secondary tumours. Metastasis results in nearly 90% of cancer related deaths 4. 
 Cell migration begins with an initial protrusion of the plasma membrane. These 
protrusions attach to the substratum through newly formed focal adhesions to provide 
traction, while the mature focal adhesions at the rear or lagging end of the cell 
disassemble to aid in retraction of the rear. As this process repeatedly occurs, the cell 
translocates across the substratum 1-3. The initial steps of cell migration rely on the 
localization of polarity proteins to establish the front or leading edge of the cell and 
promote reorganization of the cytoskeleton towards the direction of migration. The entire 
cytoskeleton acts in concert for proper cell migration, but actin polymerization provides 
the primary force for generating the cellular protrusions. The localization of Rac1 and 
Cdc42 to the leading edge initiates signaling cascades to activate actin-binding proteins 
and stimulate actin polymerization. Formin, and formin homologs increase 
polymerization rates by facilitating monomer addition to the barbed end of actin 
filaments and generally contribute to forming linear filamentous actin arrays 5,6. During 
cell migration, these linear or unbranched actin arrays form long, spike-like, protrusions 
known as filopodia, which probe the environment and act as sensors 35,36,43. In contrast, 
Rac1 activates actin related proteins 2 and 3 (Arp2/3), promoting them to bind to pre-
existing actin filaments and act as additional sites of polymerization 7,8. This generates a 
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rapidly polymerizing branched array of actin, which allows formation of lamellipodia, 
which are broad, fan-like, protrusions that drive the cell forwards 1-3,9.  
The actin cytoskeleton is a potential target for tumour cell migration, an important 
aspect of metastasis; however there are still no actin targeting compounds used in 
chemotherapy 10,11. We have previously demonstrated that TBE-31 binds to actin, 
disrupts actin polymerization, and inhibits tumour cell migration 12. In this study we aim 
at identifying the binding site(s) in actin implicated in interactions with TBE-31, thus 
allowing a better understanding of its mechanism(s) for inhibiting actin polymerization. 
TBE-31 contains αβ-unsaturated carbonyl groups in their A and C rings. These 
functional groups suggest that TBE-31 may undergo Michael addition with nucleophilic 
targets containing reactive sulfhydryl residues (Figure 4.1). Indeed, previous studies 
demonstrated TBE-31 reacts directly with the sulfhydryl groups of dithiothreitol (DTT), 
suggesting TBE-31 may interact with proteins through reactive cysteines 13-16. Further 
research, demonstrated spectroscopically that both the cyano enone functions on ring A 
and C of TBE-31 react with cysteine residues in Keap1, resulting in the transcriptional 
activation of cytoprotective genes 15,17,18. However, no specific cysteine residue(s) were 
identified in those studies. With these previous findings in mind, we hypothesized TBE-
31 interacts with the cysteine residues of actin. In this study we use in silico docking 
simulations, mass spectrometry and mutational analyses approaches to determine that 
cysteine 374 on actin is an important contributor of its interactions with TBE-31. 
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Figure 4.1 TBE-31 proposed mechanism of interaction with cysteines 
The αβ-unsaturated carbonyl groups (highlighted in red) undergo Michael addition 
reaction with the sulfhydryl groups (SH) of cysteines forming covalent adducts 
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4.3 Materials and Methods 
4.3.1 Cell Culture, Antibodies and Reagents  
Rat2 and NIH 3T3 fibroblasts were cultured in Dulbecco’s modified Eagle’s 
Medium (DMEM). Both cell lines were cultured in a 37°C humidified incubator with 5% 
CO2, and medium was supplemented with 10% fetal bovine serum (FBS) unless 
otherwise stated. 
AlexaFluor 555-conjugated phalloidin (A34055) and anti-GFP antibodies (for 
immunofluorescence) (A6455) were purchased from Invitrogen. NeutrAvidin Agarose 
beads (29200) were purchased from Thermo Scientific. Anti-GFP (632381) for 
immunoblotting was purchased from Clonetech. Iodoacetamide was purchased from 
Bioshop (#IOD 500). Polyjet for transfection was purchased from FroggaBio 
(SL100688). CDDO-Im and TBE-31 compounds were provided by Dr. Michael B. Sporn 
(Dartmouth, NH). The plasmid encoding eGFP-Actin was a generous gift from Dr. Lina 
Dagnino (University of Western Ontario, ON, Canada). 
 
4.3.2 Affinity Pull-downs 
One mg of Rat2 protein lysates in 1 ml were incubated with 10 μM TBE-56 
(biotinylated TBE-31 or b-TBE-31) at 4°C for 16 h, followed by incubating with 25 μl of 
NeutrAvidin beads for 1 h at 4°C to isolate the proteins interacting with the biotin 
conjugate. Afterwards, the beads were thoroughly washed, and 30 μl of 2X Laemmli 
sample preparation buffer was added. These samples were then subjected to denaturing 
polyacrylamide gel electrophoresis, and transferred to membranes that were probed with 
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anti-actin or anti-GFP antibodies. For studies utilizing iodoacetamide to block cysteines 
before pulldown analysis, the lysates were incubated with various concentrations of 
iodoacetamide for 4h on ice before incubating with TBE-56 and proceeding as above. For 
studies isolating the eGFP-Actin and the cysteine to alanine mutants, the plasmids were 
transfected into Rat2 cells for 24h before lysis. It was necessary in these experiments to 
include 1M Tris-Cl in the lysis buffer to ensure all samples contained monomeric actin 
irrespective of which individual cysteine to alanine mutant was analyzed. 
 
4.3.3 Computational Analysis 
The crystal structure of a complex between actin and cytochalasin D was obtained 
from the protein data bank (PDB code 3EKS) 19. Cytochalasin D was removed and 
docking simulations were carried out using SwissDock 20. All cysteines were assessed to 
verify if they are solvent exposed and the number of binding sites for TBE-31 and their 
affinities were recorded (appear as  ΔG). 
 
4.3.4 Mass Spectrometry Analysis 
 Actin purified from human platelets was purchased from Cytoskeleton Inc 
(aphl99). This actin incubated with either 50-fold molar excess of TBE-31, 
iodoacetamide or the equivalent volume of DMSO, and was processed for mass 
spectrometry analysis. Mass spectra were generated using a QTof Micro mass 
spectrometer (Waters) equipped with a Z-spray source and run in positive ion mode with 
an Agilent 1100 HPLC used for LC gradient delivery.  For LC-MS/MS, the protein was 
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cleaved with either trypsin or chymotrypsin and analysis in MASCOT combined both set 
of fragments to improve overall coverage of the protein. 
 
4.3.5 Mutagenesis 
Cysteine (C) residues in eGFP-labelled human actin (Addgene) were mutated to alanine 
(A) using the Quickchange mutagenesis kit (Agilent Technologies) according to 
manufacturer guidelines. All mutants were transformed into a XL1 Blue strain of 
Escherichia coli, amplified, purified by the Qiagen Miniprep Kit (Qiagen), and their 
sequences were verified at the London Regional Genomics Centre (London, ON, 
Canada). 
 
4.3.6 Immunofluorescence microscopy 
In all immunofluorescence microscopy studies, cells were fixed in 4% 
paraformaldehyde for 10 min, permeabilized in 0.25% Triton X-100 for 5 min, blocked in 
10% FBS, and immunostained overnight with the appropriate primary antibodies. All 
images were taken with an Olympus IX81 inverted epifluorescence microscope. 
Quantitations for cells with actin stress fibers were quantitated into three categories, 
strong stress fibers, weak stress fibers, and none. Quantitations were carried out in the 
green channel for GFP. 
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4.3.7 Transwell cell migration assays. 
NIH3T3 cells were transfected with equal amounts of plasmids encoding either 
the eGFP-Actin or eGFP-Actin-C374A. After 24h, the cells were serum starved for 4h 
prior to being seeded onto the top of a Transwell chamber (Costar). A total of 50,000 
cells per condition were seeded and allowed to migrate toward the bottom chamber, 
which contained medium supplemented with 10% serum for 18h. The upper and lower 
chamber also contained either DMSO (vehicle) or TBE-31 (0.5 μM). In parallel, 50,000 
cells from each condition were seeded onto coverslips in medium containing 10% serum 
to monitor transfection efficiency, or in serum free medium containing either DMSO or 
0.5 μM TBE-31, to monitor cell viability. After 18 h, the cells on the upper side of the 
Transwell membrane were removed with a cotton swab, and the cells that had migrated 
through the insert (i.e. on the underside of the Transwell membrane) were fixed with 4% 
paraformaldehyde. Cells on both the Transwell membrane and coverslips were stained 
with DAPI (4′,6′-diamidino-2-phenylindole) and mounted onto glass slides. Images were 
acquired using an IX81 inverted microscope (Olympus). Ten representative fields were 
acquired at ×100 magnification (approximate field of view of 59, 000 μm2) and 
quantified by counting the blue nuclei, or green fluorescent cells. 
 
4.3.8 Statistical analysis 
All quantitation carried out in this study was analyzed using one-way ANOVA.  
Statistical significance (p<0.05) for all quantitation is indicated with an asterisk (*).
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4.4 Results 
4.4.1 Iodoacetamide interferes with TBE-31 binding to actin 
 TBE-31 has been suggested to interact with proteins through cysteine residues via 
a Michael addition 14,17. To verify whether this is true of actin, we used iodoacetamide—a 
cysteine alkylating agent—to pretreat lysates before using in pull-down assays to assess if 
there would be an effect on TBE-31 binding to actin. In brief, Rat2 lysates were 
incubated with increasing concentrations (1-10 mM) of iodoacetamide, prior to a 
subsequent incubation with biotin labeled TBE-31 (TBE-55) and drug-bound complexes 
were isolated using NeutrAvidin-agarose beads. The samples were then processed for 
SDS-PAGE, and transferred to membranes that were probed for actin (Figure 4.2A). 
Concentrations of iodoacetamide of 5 mM and 10 mM significantly inhibited the pull-
down of actin by the biotin labeled TBE-31 by 50.64 ± 9.68% (P≤0.01) and 66.50 ± 
8.87% (P≤0.001) respectively (Figure 4.2B), thus supporting the notion that TBE-31 
binds to actin through cysteine thiol groups. 
 
4.4.2 TBE-31 is predicted to bind to cysteines using computer 
simulation analyses 
 To complement the above findings, we next sought to use computational 
simulation of the potential cysteines in actin that TBE-31 was likely to bind. SwissDock 
(Swiss Institute of Bioinformatics) 20 was used to model TBE-31 binding to the crystal 
structure of actin (3EKS) 19 acquired from the protein databank (PDB) server. The actin 
structure was originally determined from actin crystalized in the presence of   
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Figure 4.2 Iodoacetamide interferes with TBE-31 binding 
A) Rat2 fibroblast lysates were incubated with a 0-10 mM iodoacetamide for 1h, and then 
incubated with 10 µM biotin labeled TBE-31 (TBE-56) overnight before precipitating 
with NeutrAvidin-agarose beads. The samples were then subjected to SDS-PAGE and 
immunoblotted for Actin. Shown are representative immunoblot (n=3). 
B) Experiments carried out as described in Panel A were quantitated and graphed by 
dividing the amount of Actin pulled-down relative to the iodoacetamide free control. 
Error bars represent  the mean +/- SEM. **P< 0.01, *** P<0.001. 
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cytochalasin D (a bona fide actin depolymerizing agent), however for our analysis the 
cytochalasin D was removed. Of the > 40 potential TBE-31-actin interacting regions, the 
majority of the putative binding sites were predicted to reside in the same cleft that is 
targeted by cytochalasin D.  More importantly, association of TBE-31 in this cleft 
positions this drug to interact with Cys 374, at the C-terminus of actin (Figure 4.3A). 
Other potential cysteines include Cys 217, Cys 272, and Cys 285, with binding affinities 
calculated to be ΔG -7.5, ΔG -6.8, ΔG -6.3 and ΔG -6.2  kcal/mol respectively (Figure 
4.3B and 4.3C). With these potential targets in mind, we next sought to verify which 
cysteines were important for TBE-31 binding using a mass-spectrometry approach and 
mutational pull-down analyses. 
 
4.4.3 Mass Spectrometry Analysis 
We previously showed TBE-31 interacting with purified actin through an in vitro 
pulldown approach 12. Although the actin preparation used in this approach was 99% 
pure, there is a possibility that the interaction of TBE-31 and actin may occur through an 
intermediate actin-binding protein. We therefore attempted to assess if TBE-31 binding to 
actin was direct and if so, determine the stoichiometry of the interaction. In brief, purified 
actin was incubated with a 50-fold molar excess of, TBE-31, iodoacetamide as a positive 
control and an equivalent volume of DMSO as a vehicle control. Afterwards, the samples 
were subjected to Liquid Chromatography Mass Spectroscopy analysis (LC-MS), and the 
average masses of the complexes analyzed were measured. The average  
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Figure 4.3 Modelling TBE-31 interaction with actin 
A) Cytochalasin D bound Actin PDB file (3EKS) (right image) was used in SwissDock to 
model binding sites between TBE-31 and actin (left image) 
B) Actin PDB file (3EKS) with TBE-31 bound, and cysteines highlighted 
C) Summary of information for the cysteines on actin 
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mass of actin (Figure 4.4A) was determined to be 41661.52 ± 0.91 Da. The 
iodoacetamide treated samples (Figure 4.4C) contained additional species at molecular 
masses of 41719.56 ± 0.21 Da and 41776.32 ± 0.75 Da, which correspond to the addition 
of one (+57 Da) or two (+114 Da) iodoacetamide molecules after forming a Michael 
addition. Similarly, incubation with TBE-31 (Figure 4.4B) resulted in the appearance of a 
species with molecular mass of 41992.39 ± 0.64 Da (+330.38 Da), which corresponds to 
the addition of one molecule of TBE-31. These results confirm that TBE-31 binds to 
actin, and the presence of only one shifted molecular mass peak suggests that only one 
molecule of TBE-31 binds to one molecule of actin.  
 We next sought to determine which cysteine TBE-31 is interacting with. Purified 
actin was incubated with DMSO, and TBE-31 as above, and then digested with trypsin or 
chymotrypsin. The fragment sizes were determined by tandem Mass Spectroscopy (MS-
MS) and the data were analyzed to find fragments with an increase in mass corresponding 
to the molecular weight of TBE-31. By combining the predicted fragments from the 
chymotrypsin and trypsin analyses, the overall coverage for actin (Figure 4.5A) was 
greater than 90%. However, although the overall coverage was high, fragments 
containing the surface exposed cysteines were relatively underrepresented. Indeed, there 
were only two fragments containing the last cysteine (Cys 374; Figure 4.5B). Since this 
analysis yielded inconclusive results and any potential binding sites observed in TBE-31-
shifted actin fragments were also observed in the DMSO control, it was necessary to 
develop another method to determine which cysteine(s) on actin were responsible for 
interacting with TBE-31.   
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Figure 4.4 Mass Spectrometry analysis reveals TBE-31-Actin interaction 
A) Mass of actin protein after incubation with DMSO as determined by liquid 
chromatography followed by mass spectrometry. 
B) Mass of actin protein after incubation with 50-fold molar excess TBE-31 as 
determined by liquid chromatography followed by mass spectrometry. 
C) Mass of actin protein after incubation with 50-fold molar excess iodoacetamide as 
determined by liquid chromatography followed by mass spectrometry. 
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Figure 4.5 LC-MS/MS analysis of TBE-31-actin interaction 
A) Sequence coverage (blue) of actin (grey) after incubation with 50-fold molar excess 
TBE-31 or DMSO vehicle control, obtained by LC-MS/MS merged analysis of the 
peptide mixture obtained after separate trypsin and chymotrypsin digest. 
B) Cropped view of analysis from above to highlight the cysteines. 
C) Legend for post-translational modifications, with TBE-31 highlighted in red 
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4.4.4 Mutation of cysteine-374 interferes with TBE-31 binding to 
actin 
A series of vectors encoding actin forms with cysteine to alanine mutation at 
positions 217 (C217A), 257 (C257A), 272 (C272A), 285 (C285A), and 374 (C374A) 
were generated, which includes all but one of the cysteines in actin. Based on our above 
analysis, double mutants were also generated at cysteine 272 and 374 (C272A/C374A); 
and cysteine 285 and 374 (C285A/C374A; Figure 4.6A). Each plasmid was sequenced to 
verify the intended mutations were present. These vectors were then transfected into Rat2 
fibroblasts, and cell lysates were processed for pull-down analyses (Figure 4.6B) as done 
previously 12. Using this approach, we observed that significantly less (60.61±9.02%) 
C374A actin associated with the biotinylated-TBE-31, compared to the wild-type actin 
control (Figure 4.6C). Similarly, actin containing double cysteine mutants (that had 
C374A mutation in common) showed a comparable reduction as the single C374A 
mutant, thus suggesting that cysteine 374 is important for actin interaction with TBE-31. 
 
4.4.5 Cysteine-374 is necessary for efficient actin polymerization 
We next characterized actin containing the cysteine-374 mutation.  We first 
assessed its ability to contribute to stress fibers in migrating cells.  In brief, eGFP-Actin, 
eGFP-Actin-C257A, eGFP-Actin-C272A or eGFP-Actin-C374A was overexpressed in 
NIH3T3 cells, fixed and probed with phalloidin and anti-GFP antibodies. Using 
immunofluorescence imaging we observed robust stress fibers in the eGFP-Actin WT or 
mutant overexpressing cells (Figure 4.7A). Indeed, the eGFP-Actin was incorporated into 
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Figure 4.6 Cysteine to alanine mutation on cysteine 374 interferes with TBE-31 
interaction 
A) Schematic of eGFP-Actin (top), and the cysteine (C) to alanine (A) mutants generated 
B) Rat2 fibroblasts were transfected with the indicated plasmids and lysed. One 
milligram of lysate then incubated with 10 µM of biotin labeled TBE-31 (TBE-56) for 
16h before being pulled-down with NeutrAvidin-agarose beads. The samples were then 
processed and subjected to SDS-PAGE and immunoblotted for green fluorescent protein. 
Shown here are representative immunoblots (n=5). 
C) Quantitations of the above experiments were carried out by dividing the amount of 
GFP-Actin pull down by the input and expressed as a relative amount compared to the 
WT pulldown (n=5). Error bars represent SEM. **P<0.01. 
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Figure 4.7 eGFP-C374A-actin demonstrates poor stress fiber incorporation 
A) NIH3T3 cells were transfected with GFP-Actin, or GFP-Actin-C374A. After 48h the 
transfected cells were processed for immunofluorescence imaging and probed with 
phalloidin (red) for actin stress fibers, and anti-GFP (green) for GFP. Scale bars represent 
10 microns. 
B) Quantitation of experiments carried out as described in Panel A were carried out for 
cells containing either strong, weak or no stress fibers. GFP-ActinC257A, and GFP-
Actin-C272A were included as controls. Errors bars represent the mean ± SEM. P<0.001 
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the stress fibers, indicating that overexpression of actin did not alter stress fiber 
formation. However, the eGFP-Actin-C374A overexpressing cells mostly had an absence 
of stress fibers. Quantitation of cells containing either strong, weak or no stress fibers 
(Figure 4.7B) was then carried out. The eGFP-Actin expressing cells contained roughly 
equal proportions of all three stress fiber forms; 30.68 ± 1.61% of cells had strong stress 
fibers, 33.47 ± 1.49% of cells had weak stress fibers, and 35.85 ± 1.38% of cells had no 
stress fibers. The eGFP-Actin-C374A expressing cells contained significantly fewer cells 
with strong stress fibers, and a significantly greater number of cells with no stress fibers; 
with only 6.96 ± 0.86% and 70.62 ± 5.56% respectively. eGFP-Actin-C257A and eGFP-
Actin-C272A expressing cells were also quantitated, but neither showed significant 
difference for any of the categories when compared to the eGFP-Actin wild type control. 
This suggests cysteine 374 is important for actin polymerization and stress fiber 
formation. 
These findings were supported by the literature. Cysteine 374 in actin may be 
involved in the formation of actin dimers, and post-translational modifications that 
normally occur on cysteine 374 are associated with lower rates of polymerization and 
weakening of actin filaments 21,22. Therefore, the mechanism of action for TBE-31 on 
actin polymerization, and possibly cell migration, could potentially be interrogated using 
eGFP-Actin-C374A in a cell overexpression model. 
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4.4.6 Transwell Cell Migration Assays 
We previously demonstrated that TBE-31 interacts with actin and inhibits cell 
migration. In brief, NIH3T3 cells were transfected with vectors encoding eGFP-Actin or 
eGFP-Actin-C374A, and 50, 000 of these cells were seeded into Transwell inserts after 
24h. The top chamber contained serum free medium, whereas the bottom chamber 
contained either serum free medium, or medium supplemented with 10% FBS as a 
chemoattractant. DMSO or TBE-31 (0.25 or 0.5 μM) was added to both upper and lower 
chambers. The cells were given 18h to migrate before fixing the membrane, staining with 
DAPI and mounting for immunofluorescence analysis (Figure 4.8A)  
For each condition, the fraction of all cells that migrated through the insert was 
first determined from the number of DAPI-stained nuclei (Figure 4.8B). For cells 
expressing eGFP-Actin, the DMSO control treatment showed an average of 627.8 ± 52.8 
cells that had migrated per field, whereas with the 0.25 µM or 0.5 μM TBE-31 treatment, 
cell number decreased to 559.38 ± 59.9 and 322.8 ± 57.5 cells per field, respectively. 
Similarly, the cells expressing eGFP-Actin-C374A treated with DMSO control, had an 
average of 606.9 ± 65.0 cells per field, whereas the 0.25 µM or 0.5 µM TBE-31 treatment 
again reduced the total number of cells that migrated through the insert to 511.7 ± 38.2 
and 284.6 ± 44.5, respectively.  
The total number of transfected cells was also determined by scoring GFP-
expressing cells (Figure 4.8C). Interestingly, the proportion of cells expressing either 
eGFP-Actin or eGFP-Actin-C374A was not affected by TBE-31 compared to cells not 
expressing eGFP-labeled actin. Furthermore, cells expressing either form of actin 
responded in a similar way to TBE-31 treatment. These results show that TBE-31 does 
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Figure 4.8 Transwell cell migration with eGFP-Actin and eGFP-Actin-C374A 
A) NIH3T3 cells were transfected with eGFP-Actin or eGFP-Actin-C374A. After 24h, 
the cells were serum starved for 4h before seeding into the transwells. The top chamber 
contained serum free media, while the bottom contained 10% serum. Either DMSO, or 
TBE-31 (1mM) was added into both compartments. After 18h of cell migration, the 
membranes were excised and prepared for immunoflouresence imaging. Images were 
taken at 100x magnification. 
B) Quantitation of the entire population of cells by counting the nuclei in the experiment 
above. Errors bars represent the mean ± SEM. *P<0.05, **P<0.01 compared to the 
DMSO control. (n=4) 
C) Quantitation of the eGFP-Actin or eGFP-Actin-C374A population by counting cells 
fluorescing green in the experiment above. Errors bars represent the mean ± SEM.. (n=4) 
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inhibit cell migration as we have shown in the past with other techniques .  However, 
overexpressed actin, regardless of whether it can bind to TBE-31 or not, confers some 
resistance towards TBE-31-dependent inhibition of migration.  
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4.5 Discussion  
In this study we demonstrated that iodoacetamide, a cysteine alkylating agent, 
interferes with the ability of TBE-31 to interact with actin. Computational analysis 
highlighted 4 cysteines as putative binding targets for TBE-31. Two approaches were 
used to validate these potential binding targets, a mass spectrometry, and a mutagenesis 
based approach. With the mass spectrometry approach, we were able to successfully 
demonstrate that incubation of actin with TBE-31 was able to form a new mass 
corresponding to the mass of actin and TBE-31 together. The absence of a second peak 
corresponding to the mass of two TBE-31 molecules and actin, suggests only one 
molecule of TBE-31 binds per molecule of actin. The same conditions were submitted for 
tandem MS/MS to identify which cysteine TBE-31 is interacting with, but the results 
were inconclusive due to a lack of coverage of peptide fragments containing Cys 374. 
Thus, a mutagenesis approach was used instead to determine which cysteine TBE-31 
interacts with. A pull-down analysis was used with a panel of cysteine to alanine 
mutations, and the eGFP-Actin-C374A showed a significant reduction in pull-down by 
biotin labeled TBE-31. Further analysis of this C374A mutant showed impaired 
incorporation of this actin form into stress fibers, with the majority of cells containing 
either weak or no eGFP-Actin-C374A stress fibers. This suggested that this actin mutant 
would exhibit impaired incorporation into actin microfilaments. Transwell migration 
assays were conducted and the number of cells migrating through the transwells was 
significantly reduced by TBE-31. Taken together, these results suggest that TBE-31 
interacts with actin through Cys 374 to inhibit actin polymerization and this may be a 
mechanism wherein TBE-31 utilizes to inhibit cell migration. 
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Our findings showing impaired incorporation of eGFP-Actin-C374A into stress 
fibers is consistent with the literature. Cys 374 has been reported to have an important 
role in establishing intermonomer contacts and may stabilize the interstrand relation in 
the actin filament 23,24. Furthermore, redox modification of Cys 374 has also been linked 
to intramolecular disulfide bond formation, decreased polymerization rates, increased 
critical concentrations and filament weakening 21. Indeed, S-(cysteine-374)glutathionyl 
actin was found to form filaments of low mechanical stability 22. An analysis of 
tetramethylrhodamine(TMR)-labeled actin at Cys 374 showed TMR-actin polymerized in 
very short filaments, which were easily destabilized by ATP hydrolysis. The critical 
concentration for polymerization of TMR-actin were found to be an order of magnitude 
higher than that of unlabeled actin. In addition the interaction of actin with a number of 
actin regulating proteins was profoundly altered by TMR labeling 25. Interestingly, the 
modification of Cys 374 has been implicated in the regulation of the actin cytoskeleton 
reorganization during cell adhesion and cell spreading 26, which are important processes 
in cell migration 1-3. Therefore the notion of TBE-31 interacting with actin through Cys 
374 to impair actin polymerization and inhibit cell migration is consistent with the 
literature. 
Interestingly, the overexpression of eGFP-Actin or eGFP-Actin-C374A reduced 
the inhibitory effects of TBE-31 on cell migration, even though only the wild-type eGFP-
Actin should associate efficiently with TBE-31. In my previous studies (Chapters 2 and 
3) we showed that TBE-31 has many putative binding targets 12. We have examined the 
effects of TBE-31 on the microtubule network, vesicle trafficking, and front-rear polarity, 
and demonstrated that TBE-31 disrupts all of these 27. Perhaps cell migration cannot be 
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fully recovered from this multi-targeted drug by simply overexpressing eGFP-Actin-
C374A, because it is inhibiting cell migration through multiple proteins. However, since 
actin microfilaments are essential for cell migration, and modification of actin at Cys 374 
negatively effects actin polymerization, further studies on the effects of TBE-31 on the 
actin cytoskeleton are warranted. Our previous studies (Chapter 2) have shown that stress 
fiber formation in the presence of TBE-31 results in short filaments, which is consistent 
with the analysis of TMR-actin 25. It may be interesting to examine the stability of the 
TBE-31 modified actin filaments by using electron microscopy or measuring ATP 
hydrolysis by the filament as done previously by Conchaudron et al 25. 
A purified source of actin, and actin containing the cysteine to alanine mutations 
will open many avenues of experiments. We previously sought to generate a purified 
source of GST-actin and the cysteine mutants. We successfully excised the actin 
sequence from our eGFP vectors, and inserted them into a pGEX-4T-1 GST vector. They 
were then successfully expressed in BL21 competent cells, lysed and the GST tagged 
protein was precipitated with glutathione beads. However, despite using multiple 
approaches the elution of the protein from the beads was not successful. The approaches 
included using thrombin to cleave the protein from the GST, gradients of Triton X-100, 
guanidine and urea—strong denaturing agents, glutathione, and high salt concentrations. 
Only by using a combination of the above was a small amount of protein eluted and its 
activity seemed compromised—most likely due to improper refolding after using the 
denaturing agents. Future attempts at purifying actin and the cysteine mutants may be 
more fruitful by using a polyhistidine-tag instead of a GST-tag, and a baculovirus/SF9 
cell expression system. Once the purified protein is obtained, in vitro actin 
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polymerization assays can be performed to perhaps demonstrate a dampened effect by 
TBE-31 in the cysteine mutants. In addition, mass spectrometry analysis can be used with 
the mutants to show changes (or lack of) in the whole protein mass shift, or fragment 
labeling. 
Tandem MS/MS was not conclusive in determining which cysteine on actin TBE-31 
interacts with. The relatively low amount of TBE-31 labeled actin, compared to unlabeled 
actin in the samples, was especially problematic considering the poor coverage of Cys 
374. We attempted to address this by analyzing actin cleaved with chymotrypsin, or 
trypsin. Future experiments using other endoproteinases (for e.g., AspN) may generate 
peptides that yield better coverage. In addition, a bottom-up approach for analysis has 
been proposed where a synthesized N-terminal fragment containing Cys 374 could be 
labeled with TBE-31 and analyzed by Mass Spectroscopy. This can be used to test if the 
fragment and TBE-31 can withstand the ionization energy of MS/MS and be amenable 
for analysis. 
Overall, this study provides novel insight on the underlying mechanisms by which 
TBE-31 utilizes to inhibit cell migration. It was demonstrated that TBE-31 interacts with 
actin through Cys 374, which is necessary for efficient actin polymerization and stress 
fiber formation. Thus making TBE-31 an attractive candidate for targeting the actin 
cytoskeleton and tumour cell migration in metastasis. 
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5 Chapter 5 
5.1 Summary 
Cancer arises from cells that have undergone multiple genetic mutations that lead 
to the loss of normal cellular behaviour 1,2. These mutations initially result in 
uncontrolled growth and proliferation.  As the malignant cells continue to gain genetic 
mutations, some cells will gain the ability to migrate and invade adjacent tissue, and 
disseminate to distant organs where they may establish new tumour colonies. These 
colonies are known as metastases, and are responsible for over 90% of human cancer 
related deaths 3-6.  Cell migration is a key process in promoting metastasis, and to date 
effective drugs targeting metastasis are lacking 6-10. 
Synthetic oleanolic acid agents have received notable attention in recent years for 
their multiple anti-tumourigenic effects, which include inducing apoptosis, reducing 
inflammation, and inhibiting proliferation of tumour cells. Studies in our laboratory have 
also demonstrated that the specific synthetic oleanolic acid derivatives, CDDO-Im and 
CDDO-Me, target the cytoskeleton and inhibit cell migration 11,12. More recently, 
medicinal chemists have synthesized a class of three ring compounds known as TBEs. 
They resemble the CDDO compounds and contain the same active regions responsible 
for their potency. TBE-31 was found to be particularly potent in anti-inflammatory 
assays, and many studies have outlined the effects of TBE-31 on the KEAP1/Nrf2 
pathway. However their effects on cell migration were entirely unknown. Given their 
structural similarities to the CDDO compounds, I hypothesized that TBE-31 will inhibit 
cell migration by targeting components of the cytoskeleton. The three specific aims I 
designed to address this hypothesis were to: 
191 
 
1) Characterize the effect(s) of TBE-31 on the actin cytoskeleton and cell 
migration. 
2) Characterize the effect(s) of TBE-31 on the structure and dynamics of the 
microtubule network and cell migration. 
3) Determine how TBE-31 interacts with actin. 
 
Data from experiments designed to address aims 1, 2, and 3 are presented in 
chapters 2, 3, and 4 respectively, and are briefly summarized below. 
 
Arp2/3 is involved in the actin polymerization and the formation of the 
lamellipodia in cell migration 1,2,13. CDDO-Im and CDDO-Me have been shown to 
interact with Arp3, inhibit Arp2/3 activity and localization to the leading edge 12. In 
chapter 2, I determined that, unlike CDDO-Im or CDDO-Me, TBE-31 does not alter 
Arp3 localization to the leading edge. Using TBE-56 (biotin labeled TBE-31), I identified 
a number of putative protein binding partners. Of the identified proteins, actin was of 
particular interest as it is provides the force for generating cellular protrusions and 
establishing lamellipodia, key events for cell migration. The interaction between TBE-31 
and actin was further validated and the results obtained suggested TBE-31 is able to 
associate with actin. I then demonstrated that TBE-31 is able to inhibit actin 
polymerization using an in vitro assay and inhibit actin stress fiber formation in NIH 3T3 
fibroblasts, which is entirely unique effect from CDDO-Im or CDDO-Me. These findings 
were then applied to the model of epithelial-to-mesenchymal transition (EMT), a 
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precursor event to cancer metastasis. TGFβ was used to induce EMT in A549 lung cancer 
cells, and the rearrangement of cortical actin to actin stress fibers was inhibited by TBE-
31. Lastly I demonstrated using scratch assays, and single cells, that TBE-31 is effective 
in inhibiting H1299 lung cancer cell, and NIH 3T3 cell migration for the first time. 
In chapter 3, I identified tubulin to bind to TBE-31. However, unlike actin, TBE-
31 was not found to inhibit the polymerization of tubulin, but instead it was found that 
TBE-31 alters the organization of the microtubule network and its dynamics. 
Microtubule-dependent processes were then investigated and TBE-31 was shown to 
disrupt microtubule-dependent trafficking. I then demonstrated that TBE-31 alters front-
rear polarity in migrating cells, in a manner distinct from CDDO-Im. TBE-31 treated 
cells were observed to form multiple protrusions of active Rac1, whereas CDDO-Im 
reduces active Rac1 localization at the membrane. Since a single dominant leading edge 
is necessary for efficient directed cell migration, I then demonstrated that TBE-31 
inhibited cell migration of Rat2 fibroblasts. 
In chapter 4, the focus was on better understanding the biochemical interaction 
between actin and TBE-31 to determine the mechanism(s) in which TBE-31 utilizes to 
inhibit actin polymerization and cell migration. Previous work has suggested that TBE-31 
may undergo Michael addition with nucleophilic targets containing reactive sulfhydryl 
groups (thiols) 14,15. However, no previous work has identified any specific cysteines on 
any proteins. By blocking the thiol groups on actin with a cysteine alkylating agent, the 
interaction between TBE-31 and actin was inhibited. Thus suggesting TBE-31 interacts 
with actin through cysteine thiol groups. This finding was supported by data from 
computational simulations. Furthermore, cysteine 374 was identified as a potential 
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candidate. Using mass spectrometry, it was determined that one molecule of TBE-31 
interacts with one molecule of actin. LC/MS-MS was used to try to determine the exact 
cysteine(s) TBE-31 interacts with, however due to limitations of the technique this was 
not possible. Instead a pull-down approach was utilized with wild-type or mutated GFP-
actin. I determined that TBE-31 interacts with actin through cysteine 374, marking this as 
the first ever identified target at the amino acid level. Characterization of the GFP-actin-
C374A, demonstrated that cysteine 374 is necessary for efficient actin stress fiber 
formation. This suggests it may important for actin polymerization, which is supported by 
past research by others 16-19. The final experiment of this chapter attempted to interrogate 
the exact mechanism of action for TBE-31 on cell migration by overexpressing GFP-
actin-C374A. Although these results confirmed TBE-31 inhibits cell migration using a 
third technique, they were not able to clearly demonstrate a recovery effect by 
overexpression, as the control GFP-actin reduced the effects of TBE-31 as well. 
However, the notion of TBE-31 interacting with actin through cysteine 374 to impair 
actin polymerization and inhibit cell migration is consistent with other studies on cysteine 
374 modification on actin 20,21. 
 
5.2 Limitations and Future Experiments 
In this thesis, I demonstrated that TBE-31 interacts with the thiol groups of 
reactive cysteines, thus TBE-31 is a multi-targeting drug. Indeed, in chapter 2 and 3, a 
number of putative binding targets for TBE-31 were identified. Due to the multi-targeted 
nature of this drug, it was difficult to attribute specific phenotypic changes to specific 
targets. For instance, since the microtubule network and the actin cytoskeleton are 
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intimately linked, it is difficult to attribute the mislocalization of the polarity proteins 
specifically to the microtubule network alone. Future studies examining the effects of 
TBE-31 on other proteins, and other processes should keep this caveat in mind. For this 
reason, it was helpful to study the proteins in isolation in in vitro polymerization assays. 
Indeed, this approach was useful for the heavily mechanistic nature of my studies, and 
was valuable for narrowing down the mechanisms by which TBE-31 inhibits cell 
migration. However, it is important to note and remember for future studies, that these 
assays may not fully reflect what happens in vivo. In the cell, the cytoskeleton is tightly 
regulated in time and space by a large number of signaling, scaffolding and binding 
proteins 22. One of the limitations encountered in this study was the inability to silence 
the expression of actin or tubulin as they are fundamental to other processes outside of 
cell migration, such as cell division and providing structure to the cell 22. In order to 
recapitulate the effects of TBE-31 on these proteins in cell migration, it may be necessary 
to silence their regulatory proteins instead. For instance, formin and profilin which 
enhance general actin polymerization rates 23, can be silenced in lieu of actin. Similarly, 
another limitation of this study was the inability to properly overexpress GFP-actin-
C374A. Due to the nature of the mutant, only low-to-medium levels of expression were 
tolerated before the actin cytoskeleton was compromised. This may explain why a 
recovery effect was not observed when GFP-actin-C374A was overexpressed in the 
transwell migration assays carried out in chapter 5. Future studies may need to resort to 
using an in vitro polymerization assays with a purified source of actin-C374A instead. 
The C374A mutant would be expected to have lower intrinsic rates of polymerization, but 
since TBE-31 does not interact with the mutant, it is expected that this rate of 
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polymerization will be unaffected by TBE-31. Thus determining the specific mechanism 
in which TBE-31 inhibits actin polymerization. 
 A major focus of my thesis was on the effects of TBE-31 on cell migration. 
Multiple approaches were used to assess this, including scratch assays, single cell 
migration, and transwell migration assays. It is important to identify the caveats and 
limitations of each technique as used in these studies. Scratch assays may be influenced 
by rates of cell proliferation. The studies addressed this by tracking single cells in sub 
confluent migration assays. However a caveat of this technique is that it is dependent on 
the cell type’s inherent predilection for exploring the environment, since no stimulus is 
present to induce cell migration. Transwell assays permit chemotaxis and is an excellent 
model for directed cell migration, but because the cells are usually fixed and stained in 
order to be quantified, they are endpoint assays. They cannot provide kinetic data as 
easily as the scratch and subconfluent cell migration assays do. Therefore this assay 
cannot distinguish between cells that have migrated a great distance versus a short 
distance, and can only discern between cells that have or have not migrated through the 
pores of the membrane. Therefore, the studies in this thesis utilized all three of these 
techniques to complement one another and minimize the above limitations to generate 
robust data to support the hypothesis.  
Complementary future experiments may can include the use of the µ-Slide 
Chemotaxis (ibidi) system. In brief, two reservoirs are connected by a narrow observation 
area. The cells under investigation are seeded into the observation area, one reservoir is 
filled with regular media, while the other reservoir is filled with media containing a 
chemoattractant, which results in a gradient of the chemoattractant in the observation 
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area. This technique would allow for full observation over the course of the experiment—
which would allow the collection of kinetic data—would not be as prone to influence 
from cell division, and still benefit from inducing directed cell migration with a 
chemotactic gradient. 
 It is also important to note that cell motility during the metastasis cascades 
includes cell migration and cell invasion. Although the two processes share similarities, it 
is important to note differences. During invasion, instead of lamellipodia, invadopodia 
form to mediate the migration and degradation of the extracellular matrix with matrix 
metalloproteases (MMP) 24. The invadopodia is comprised of an actin-filament rich core 
and a protein complex composed of integrins and integrin-associated proteins like 
vinculin, talin and paxillin 24. In addition, scaffolding proteins such as Tks5 have also 
been identified to be specific to invadopodia 25. Therefore, cell invasion is dependent on 
migration, but may require different mechanics 24,26. My studies have demonstrated TBE-
31 as an effective inhibitor of cell migration, and warrant future experiments to include 
complementary models for cell invasion. The transwell migration assays from this thesis 
can easily be adapted to study invasion. A standard technique in the field is to coat the 
transwell inserts with Matrigel (Corning) 27, a solubilized basement membrane 
preparation, before seeding cell in the top chamber. In addition, another common 
technique is to seed the cells into a bed of Matrigel to study three dimensional cell 
culturing 28. Invasive cell lines will form protrusions to invade into the surrounding 
Matrigel. Lastly, a mixture of Matrigel and cells can be seeded into the µ-Slide 
Chemotaxis system outlined above to monitor chemotaxis directed cell invasion over 
time. Since TBE-31 targets the actin and microtubule cytoskeleton—components that are 
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also fundamental to cell invasion—it is expected that TBE-31 would inhibit invasion as 
well. 
 The in vitro cell migration techniques used in this thesis, and the in vitro cell 
migration and invasion assays proposed for future experiments above are valuable tools 
for initial studies and characterizing the effects of TBE-31. However, they may not be 
fully reflective of cell migration and invasion in vivo. For instance, cells utilize a greater 
range of protrusive structures such as blebs, lobopodia and pseudopods to squeeze 
through the extracellular matrix in vivo instead of forming only lamellipodia 29,30. The 
varying substratum of the extracellular matrix may provide multiple haptotactic cues, and 
multiple chemotactic agents can originate from various directions, thus further 
complicating the establishment of polarity 30. The promising results from my thesis 
justify the extension of my findings into animal models for future experiments. More 
specifically, the cancer cells can be transplanted into immunocompromised mice. A 
group of mice would receive intraperitoneal injections of TBE-31 suspended in saline 
while another group will receive equal injections of DMSO suspended in saline. After a 
period of time, organs can be harvested and examined for surface nodules, or subjected to 
histology for examination of metastatic burden. Studies such as these would examine 
metastasis as a whole, and be a more specific indication of how effective TBE-31 inhibits 
cell migration and invasion to reduce metastasis. Based on what has been demonstrated in 
this thesis, it would be expected that TBE-31 would inhibit tumour cell migration and 
invasion to reduce metastasis burden to distant organs. 
 During the study of TBE-31 on the cytoskeleton and cell migration, it was 
interesting to observe how TBE-31 has effects on the cytoskeleton unique from CDDO-
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Im and CDDO-Me. In chapters 2 and 4, I demonstrated that TBE-31 binds to actin to 
inhibit polymerization, while other studies have shown CDDO-Im and CDDO-Me target 
Arp2/3 to inhibit the induction of branched actin polymerization. Interestingly, the 
general effect of inhibiting cell migration was observed with all three. Perhaps by 
targeting actin polymerization in two different manners critical for cell migration, better 
specificity and greater potency can be achieved with a combination of these two class of 
compounds. Future studies may benefit from examining this possible synergistic effect. 
 
5.3 Significance and Conclusion 
 Metastasis accounts for over 90% of cancer related deaths. Significant progress 
has been made in understanding metastasis, however there is still a severe lack of 
therapies targeting the numerous processes involved 8-10. Most of the available therapies 
primarily focus on cancer growth 9. One potential approach is to target tumour cell 
motility as a strategy against tumour cell migration, invasion, and metastasis 31,32. 
 The synthetic triterpenoids and tricyclic compounds have gained attention in the 
recent years for their anti-inflammatory properties. Previous studies have shown the 
synthetic oleanolic acid derivatives have anti-migratory properties however the effects of 
TBE-31 on cell migration were completely unknown until now. My work has gleaned 
insight on how TBE-31 modulates various aspects of the cytoskeleton and polarity, in a 
fashion entirely unique from CDDO-Im or CDDO-Me. More specifically I demonstrated 
for the first time that TBE-31 targets the actin cytoskeleton, microtubule network, and 
polarity proteins, and inhibits tumour cell migration (Figure 5.1).  This makes TBE-31 an 
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attractive candidate for targeting tumour cell motility in cancer metastasis, and warrants 
further investigation. In addition, this knowledge will be important for developing more 
efficacious and specific tricyclic compounds and synthetic triterpenoids for targeting 
cancer metastasis. 
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Figure 5.1 The effects of the syntehtic oleanane triterpenoids and tricyclic 
compounds on cell migration 
A) A summary of previous findings on the effects of CDDO-Im on cell migration. Top, 
CDDO-Im was found to alter microtubule dynamics by disrupting the microtubule 
capping protein, Clip-170, disrupt microtubule dynamics and organization, and cause a 
loss of polarity proteins to the leading edge. Bottom, CDDO-Im was found to inhibit 
Arp2/3-dependent branched actin polymerization at leading edge. Note filopodia 
unaffected as its formation is independent of Arp2/3. 
B) A summary of the effects of TBE-31 on cell migration found in this thesis. Top, I 
determined TBE-31 directly binds to tubulin and interferes with microtubule dynamics 
and the polarity proteins Rac1, IQGAP and Tiam1 were found to localize to multiple 
conflicting locations around the cell periphery, resulting in the loss of a single dominant 
protrusion. Bottom, I determined TBE-31 binds to cysteine 374 of actin—a critical 
cysteine for filamentous actin stability—and inhibit actin polymerization. All of which I 
believe contribute to inhibiting efficient cell migration. 
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